

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199956441 B2
(10) Patent No. 760118

(54) Title
Process for enzymatically modifying pectin

(51)⁷ International Patent Classification(s)
C12P 019/04 C12N 009/18
A23L 001/0524

(21) Application No: **199956441**

(22) Application Date: **1999.09.15**

(87) WIPO No: **WO00/15830**

(30) Priority Data

(31) Number	(32) Date	(33) Country
9820195	1998.09.16	GB

(43) Publication Date : **2000.04.03**

(43) Publication Journal Date : **2000.05.25**

(44) Accepted Journal Date : **2003.05.08**

(71) Applicant(s)
Danisco A/S

(72) Inventor(s)
Tove Martel Ida Else Christensen; Anette Amstrup Pedersen; Janne Brunstedt;
Jorn Dalgaard Mikkelsen

(74) Agent/Attorney
F.B. RICE and CO.,139 Rathdowne Street,CARLTON VIC 3053

(56) Related Art
WO 97/31102
PLASTOW,G.S. MOL.MICROBIOL (1988) 2(2) P 247-254

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12P 19/04, C12N 9/18, A23L 1/0524	A1	(11) International Publication Number: WO 00/15830 (43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/IB99/01580 (22) International Filing Date: 15 September 1999 (15.09.99) (30) Priority Data: 9820195.7 16 September 1998 (16.09.98) GB (71) Applicant (for all designated States except US): DANISCO A/S [DK/DK]; Langebrogade 1, P.O. Box 17, DK-1001 Copenhagen K (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): CHRISTENSEN, Tove, Martel, Ida, Else [DK/DK]; Søengen 30, DK-3450 Allerød (DK). PEDERSEN, Anette, Amstrup [DK/DK]; Stengårds Alle 221, DK-2860 Søborg (DK). BRUNSTEDT, Janne [DK/DK]; Dueholm 18, DK-4000 Roskilde (DK). MIKKELSEN, Jørn, Dalgaard [DK/DK]; Engkær 38, DK-2650 Hvidovre (DK). (74) Agents: HARDING, Charles, Thomas et al.; D Young & Co, 21 New Fetter Lane, London EC4A 1DA (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PROCESS FOR ENZYMATICALLY MODIFYING PECTIN		
(57) Abstract A process for treating a pectin with a pectin methyl esterase (PME) is described. Here, the PME is not a plant PME – but the PME is capable of exhibiting at least one plant PME property; wherein the at least one plant PME property comprises at least block-wise de-esterification of the pectin.		

PROCESS FOR ENZYMATICALLY MODIFYING PECTIN

The present invention relates to a process.

5 In particular, the present invention relates to a process which comprises the use of an enzyme.

More in particular, the present invention relates to a process for enzymatically modifying pectin.

10

Pectin is a structural polysaccharide commonly found in the form of protopectin in plant cell walls. The backbone of pectin comprises linked (1→4)-α-D-galacturonic acid residues which are interrupted with a small number of 1→2 linked α-L-rhamnose units.

15 In addition, pectin comprises highly branched regions with an almost alternating rhamno-galacturonan chain. These highly branched regions also contain other sugar units (such as D-galactose, L-arabinose and xylose) attached by glycosidic linkages to the C3 or C4 atoms of the rhamnose units or the C2 or C3 atoms of the galacturonic acid units. The long chains of -(1→4)-α linked galacturonic acid residues are commonly referred to as
20 "smooth" regions, whereas the highly branched regions are commonly referred to as the "hairy regions".

Some of the carboxyl groups of the galacturonic residues are esterified (e.g. the carboxyl groups are methylated). By way of example, some galacturonic acid residues are esterified
25 with methanol. Typically esterification of the carboxyl groups occurs after polymerisation of the galacturonic acid residues. However, it is extremely rare for all of the carboxyl groups to be esterified (e.g. methylated).

Usually, the degree of esterification will vary from 0-90%. If 50% or more of the carboxyl groups are esterified then the resultant pectin is referred to as a "high ester pectin" ("HE pectin" for short) or a "high methoxyl pectin". If less than 50% of the carboxyl groups are esterified then the resultant pectin is referred to as a "low ester pectin" ("LE pectin" for short) or a "low methoxyl pectin". If 50% of the carboxyl groups are esterified then the resultant pectin is referred to as a "medium ester pectin" ("ME pectin" for short) or a "medium methoxyl pectin". If the pectin does not contain any - or only a few - esterified groups it is usually referred to as pectic acid.

The structure of the pectin, in particular the degree of esterification (e.g. methylation), dictates many of the resultant physical and/or chemical properties of the pectin. For example, pectin gelation depends on the chemical structure of the pectin, especially the degree of esterification. In addition, however, pectin gelation also depends on the soluble-solids content, the pH and calcium ion concentration. With respect to the latter, it is known that the calcium ions form complexes with free carboxyl groups, particularly those on a LE pectin.

Pectic enzymes are classified according to their mode of attack on the galacturonan part of the pectin molecule. A review of some pectic enzymes has been prepared by Pilnik and Voragen (Food Enzymology, Ed.: P.F.Fox; Elsevier; (1991); pp: 303-337). In particular, pectin methylesterases (EC 3.1.1.11), otherwise referred to as PME_s, de-esterify HE pectins to LE pectins or pectic acids. In contrast, and by way of example, pectin depolymerases split the glycosidic linkages between galacturonosyl methylester residues.

In more detail, PME activity produces free carboxyl groups and free methanol. The increase in free carboxyl groups can be easily monitored by automatic titration. In this regard, earlier studies have shown that some PME_s de-esterify pectins in a random manner, in the sense that they de-esterify any of the esterified (e.g. methylated) galacturonic acid residues on one or more than one of the pectin chains. Examples of PME_s that randomly de-esterify pectins may be obtained from fungal sources such as

Aspergillus aculeatus (see WO 94/25575) and *Aspergillus japonicus* (Ishii *et al* 1980 J Food Sci 44 pp 611-14). Baron *et al* (1980 Lebensm. Wiss. μ -Technol. 13 pp 330-333) apparently have isolated a fungal PME from *Aspergillus niger*. This fungal PME is reported to have a molecular weight of 39000 D, an isoelectric point of 3.9, an optimum pH of 4.5 and a K_m value (mg/ml) of 3.

In contrast, some PMEs are known to de-esterify pectins in a block-wise manner, in the sense that it is believed they attack pectins either at non-reducing ends or next to free carboxyl groups and then proceed along the pectin molecules by a single-chain mechanism, thereby creating blocks of un-esterified galacturonic acid units which can be calcium sensitive. Examples of such enzymes that block-wise enzymatically de-esterify pectin are plant PMEs. Up to 12 isoforms of PME have been suggested to exist in citrus (Pilnik W. and Voragen A.G.J. (Food Enzymology (Ed.: P.F.Fox); Elsevier; (1991); pp: 303-337). These isoforms have different properties.

Random or blockwise distribution of free carboxyl groups can be distinguished by high performance ion exchange chromatography (Schols *et al* Food Hydrocolloids 1989 6 pp 115-121). These tests are often used to check for undesirable, residual PME activity in citrus juices after pasteurisation because residual PME can cause, what is called, "cloud loss" in orange juice in addition to a build up of methanol in the juice.

PME substrates, such as pectins obtained from natural plant sources, are generally in the form of a high ester pectin having a DE of about 70%. Sugar must be added to extracts containing these high ester PME substrates to provide sufficient soluble solids to induce gelling. Usually a minimum of 55% soluble solids is required.

Syneresis may occur. By way of example, syneresis in marmalades and jams with low soluble solid content (< 55%) may occur when using HE-pectin. However, HE-pectin is not usually used in such applications. If pectins are to be used, then typically amidated pectins or LE-pectin are used, such as for jams with < 55% SS.

When syneresis does occur, expensive additives must be used to induce gelling.

Versteeg *et al* (J Food Sci 45 (1980) pp 969-971) apparently have isolated a PME from
5 orange. This plant PME is reported to occur in multiple isoforms of differing properties.
Isoform I has a molecular weight of 36000 D, an isoelectric point of 10.0, an optimum pH
of 7.6 and a K_m value (mg/ml) of 0.083. Isoform II has a molecular weight of 36200 D,
an isoelectric point of 11.0, an optimum pH of 8.8 and a K_m value (mg/ml) of 0.0046.
Isoform III (HMW-PE) has a molecular weight of 54000 D, an isoelectric point of 10.2, an
10 optimum pH of 8 and a K_m value (mg/ml) of 0.041. However, to date there has been very
limited sequence data for such PMEs.

According to Pilnik and Voragen (*ibid*), PMEs may be found in a number of other higher
plants, such as apple, apricot, avocado, banana, berries, lime, grapefruit, mandarin,
15 cherries, currants, grapes, mango, papaya, passion fruit, peach, pear, plums, beans,
carrots, cauliflower, cucumber, leek, onions, pea, potato, radish and tomato. However,
likewise, so far there has been very limited sequence data for such PMEs.

A plant PME has been reported in WO-A-97/03574 (the contents of which are
20 incorporated herein by reference). This PME has the following characteristics: a
molecular weight of from about 36 kD to about 64 kD; a pH optimum of pH 7 - 8 when
measured with 0.5% lime pectin in 0.15 M NaCl; a temperature optimum of at least 50°C;
a temperature stability in the range of from 10°- at least 40°C; a K_m value of 0.07%; an
activity maximum at levels of about 0.25 M NaCl; an activity maximum at levels of about
25 0.2 M Na₂SO₄; and an activity maximum at levels of about 0.3 M NaNO₃.

Another PME has been reported in WO 97/31102 (the contents of which are incorporated
herein by reference).

PMEs have important uses in industry. For example, they can be used in or as sequestering agents for calcium ions. In this regard, and according to Pilnik and Voragen (*ibid*), cattle feed can be prepared by adding a slurry of calcium hydroxide to citrus peels after juice extraction. After the addition, the high pH and the calcium ions activate any native PME in the peel causing rapid de-esterification of the pectin and calcium pectate coagulation occurs. Bound liquid phase is released and is easily pressed out so that only a fraction of the original water content needs to be removed by expensive thermal drying. The press liquor is then used as animal feed.

As indicated above, a PME has been obtained from *Aspergillus aculeatus* (WO 94/25575). Apparently, this PME can be used to improve the firmness of a pectin-containing material, or to de-methylate pectin, or to increase the viscosity of a pectin-containing material.

It has also become common to use PME in the preparation of foodstuffs prepared from fruit or vegetable materials containing pectin - such as jams or preservatives. For example, WO-A-94/25575 further reports on the preparation of orange marmalade and tomato paste using PME obtained from *Aspergillus aculeatus*.

JP-A-63/209553 discloses gels which are obtained by the action of pectin methylesterase, in the presence of a polyvalent metal ion, on a pectic polysaccharide containing as the main component a high-methoxyl poly α -1,4-D-galacturonide chain and a process for their production.

Pilnik and Voragen (*ibid*) list uses of endogenous PMEs which include their addition to fruit juices to reduce the viscosity of the juice if it contains too much pectin derived from the fruit, their addition as pectinase solutions to the gas bubbles in the albedo of citrus fruit that has been heated to a core temperature of 20°C to 40°C in order to facilitate removal of peel and other membrane from intact juice segments (US-A-4284651), and their use in protecting and improving the texture and firmness of several processed fruits and vegetables such as apple (Wiley & Lee 1970 Food Technol 24 1168-70), canned tomatoes

(Hsu *et al* 1965 J Food Sci 30 pp 583-588) and potatoes (Bartolome & Hoff 1972 J Agric Food Chem 20 pp 262-266).

5 Glahn and Rolin (1994 Food Ingredients Europe, Conf Proceedings pp 252-256) report on the hypothetical application of the industrial "GENU pectin type YM-100" for interacting with sour milk beverages. No details are presented at all on how GENU pectin type YM-100 is prepared.

10 EP-A-0664300 discloses a chemical fractionation method for preparing calcium sensitive pectin. This calcium sensitive pectin is said to be advantageous for the food industry.

Plastow G.S. (1988 Molecular Microbiology 2(2) 247-254) reports on a pectin methyl esterase gene of *Erwinia chrysanthemi* B374. According to the author:

15 "The isolation of the *Erwinia* gene provides a simple method for the production of PME free from depolymerizing pectinases thereby extending its potential uses".

Plastow G.S. further states that:

20 "The PME ... produced from *E.coli* supernatants has been used successfully to de-esterify high-methoxyl pectin for the production of calcium-set gels. The gels that were obtained were found to equal those made from pectate produced using enzyme extracted from orange peel (... unpublished results)."

25 Thus, pectins and de-esterified pectins, in addition to PMEs, have an industrial importance.

However, and as reported in PCT/IB98/00673 (filed 24 April 1998), a benefit derived from use of a PME in the preparation of, for example, a foodstuff will depend to some extent on the quality and quantity and type of the PME used and on the quality and quantity and type of the PME substrates - in particular pectin - that may be present in the material used to prepare the foodstuff. For example, if the substrate is a fruit material or a vegetable material then the amount and/or structure of natural pectin in that substrate will be different for different types of fruit material or vegetable material. This is also borne out by the data presented in WO-A-94/25575, especially Figure 7 where it is clear to see that its PME system is not ideal.

According to a first aspect of the present invention there is provided a process for treating a pectin with a pectin methyl esterase (PME); wherein the PME is not a plant PME; but wherein the PME is capable of exhibiting at least one plant PME property; and wherein the at least one plant PME property comprises at least block-wise de-esterification of the pectin.

According to a second aspect of the present invention there is provided a PME treated pectin prepared by the process according to the present invention.

According to a third aspect of the present invention there is provided a foodstuff comprising a PME treated pectin prepared by the process according to the present invention.

According to a fourth aspect of the present invention there is provided use of a PME as herein defined to reduce the number of ester groups in a pectin and in a block-wise manner.

According to a fifth aspect of the present invention there is provided the use of a PME as herein defined to de-esterify two or more adjacent galacturonic acid residues of a pectin on at least substantially all of the pectin chains.

The present invention also relates to any one or more of:

5 a construct expressing or comprising the PME as defined herein or the nucleotide sequence as defined herein.

a vector expressing or comprising a construct of the present invention or the PME as defined herein or the nucleotide sequence as defined herein.

10 a combination of constructs comprising at least a first construct expressing or comprising the PME enzyme as defined herein or the nucleotide sequence as defined herein; and a second construct comprising a gene of interest (GOI) and a promoter.

15 a cell, tissue or organ expressing or comprising a vector according to the present invention or a construct according to the present invention or the PME as defined herein or the nucleotide sequence as defined herein or the combination of constructs according to the present invention.

20 a transgenic organism expressing or comprising a cell, tissue or organ expressing or comprising a vector according to the present invention or a construct according to the present invention or the PME as defined herein or the nucleotide sequence as defined herein or the combination of constructs according to the present invention.

25 a recombinant PME enzyme which is immunologically reactive with an antibody raised against a PME enzyme as defined herein.

In addition to the sequences presented in the attached sequence listings (as well as fragments, derivatives or homologues thereof), the present invention also covers sequences that are complementary to the aforementioned sequence listings (as well as fragments,
30 derivatives or homologues thereof). The present invention also covers sequences that can

hybridise to the aforementioned sequence listings (as well as fragments, derivatives or homologues thereof). The present invention also covers sequences that are complementary to sequences that can hybridise to the aforementioned sequence listings (as well as fragments, derivatives or homologues thereof).

5

The present invention also relates to novel amino acid sequences and novel nucleotide sequences presented herein.

10

Preferably, those novel amino acid sequences and novel nucleotide sequences are isolated and/or purified. Here, the term "isolated" and "purified" refer to molecules, either nucleic or amino acid sequences, that are removed from their natural environment and isolated or separated from at least one other component with which they are naturally associated.

15

The present invention is based on the highly surprising finding that it is possible to obtain PME's from sources other than plants that are capable of block-wise de-esterifying pectins but wherein those PME's have plant PME like properties.

20

More in particular, the present invention is based on the highly surprising finding that it is possible to obtain PME's from bacterial sources that are capable of block-wise de-esterifying pectins.

25

The present invention is distinguishable over the teachings of, for example, Plastow G.S. (*ibid*) as that author does not disclose block-wise de-esterification of pectins. Moreover, that author refers to unpublished work that includes a comparison with an "*enzyme extracted from orange peel*" - and yet no details are provided on what enzyme, let alone enzymatic activity, is used in the comparative studies. Moreover, the reference to "calcium set" gels and the comparison to pectate produced gels in that paper indicate that the pectins were de-esterified to low ester pectins - which is in direct contrast to a highly preferred aspect of the present invention.

30

Thus, the present invention relates to a process for treating a pectin with a PME; wherein the PME is not a plant PME; but wherein the PME is capable of exhibiting at least one plant PME property; and wherein the at least one plant PME property comprises at least
5 block-wise de-esterification of the pectin.

Preferably, the PME has a molecular weight of about 36,000 D and/or a pI of about >9 and/or a pH optimum with lime pectin (as determined by the aforementioned method) of about pH 7 and/or a temperature optimum with lime pectin (as determined by the
10 aforementioned method) of about 48°C.

Preferably, the PME comprises the amino acid sequence shown as SEQ.I.D. No.2 or a variant, derivative or homologue thereof, including combinations thereof.

15 Preferably, the PME has the amino acid sequence shown as SEQ.I.D. No.2, or a variant, derivative or homologue thereof.

Preferably, the PME has the amino acid sequence shown as SEQ.I.D. No.2.

20 Preferably, the PME has been expressed by a nucleotide sequence comprising the nucleotide sequence shown as SEQ.I.D. No. 1, or a variant, derivative or homologue thereof, or combinations thereof.

Preferably, the PME has been expressed by a nucleotide sequence having the nucleotide
25 sequence shown as SEQ.I.D. No. 1, or a variant, derivative or homologue thereof.

Preferably, the PME has been expressed by a nucleotide sequence having the nucleotide sequence shown as SEQ.I.D. No. 1.

30 Preferably, the PME has been prepared by use of recombinant DNA techniques.

Preferably, the PME is obtainable from a micro-organism, preferably a bacterium.

Preferably, the pectin is treated by the PME in the presence of sodium ions.

Preferably, the sodium ions are derived from NaCl, NaNO₃ or Na₂SO₄ or combinations thereof.

Preferably, the process includes the further step of isolating the PME treated pectin from the active PME. Here, the PME treated pectin can be physically removed from the active PME or *vice versa*. Preferably, however, the PME treated pectin is isolated from the active PME by simply inactivating the PME, such as through the application of heat.

Preferably, the PME treated pectin is a high ester pectin.

Preferably, the PME treated pectin contains from about 70% to about 80% ester groups.

Preferably, the PME treated pectin contains from about 72% to about 80% ester groups.

Preferably, the PME treated pectin contains from about 74% to about 80% ester groups.

Preferably, the PME treated pectin contains from about 76% to about 80% ester groups.

Preferably, the PME treated pectin contains from about 77% to about 79% ester groups.

Preferably, the PME treated pectin contains about 78% ester groups.

Preferably, the process includes the further step of adding the PME treated pectin to a medium that is suitable for consumption.

Preferably, the medium is an aqueous solution.

Preferably, the medium is an acidic environment.

- 5 Preferably, the acidic environment has a pH of from about 3.5 to about 5.5, preferably wherein the acidic environment has a pH of from 4 to about 5.5.

Preferably, the acidic environment has a pH of about 4.

- 10 Preferably, the aqueous solution is a beverage.

Preferably, the beverage is an acidified milk drink, drinking yoghurt, a milk drink comprising fruit, or a beverage enriched with proteins, such as plant and/or dairy proteins, such as whey protein and/or soya protein. A protocol for determining the suitability of a treated pectin for use in a drink is shown after the Examples Section.

15

Acidified milk drinks with long shelf life are very popular, especially in the Far East. In some cases, a heat treatment is necessary to obtain a long shelf life. In order to avoid sedimentation of protein during and after heating, pectin is added as a stabilising agent.

20 In some applications, the quality of the acidified milk drink may depend on the properties and the concentration of the pectin used.

In one preferred aspect, the medium comprises and/or is enriched with a protein. Here, preferably, the protein is either derived from or is derivable from or is in a dairy product, such as milk or cheese - preferably wherein the protein is casein or whey protein - and/or derived from or is derivable from or is in a plant product.

25

If the beverage is an acidified milk drink, then it is typically prepared by acidifying the milk and then adding the pectin at a low pH.

If the beverage is a soya protein drink, then it is typically prepared by solubilising the soya protein at neutral pH. The pectin is added by solubilization in the soya protein solution at neutral pH. Then, the solution is acidified by addition e.g. fruit juice.

5 The use of a block-wise enzymatically de-esterified pectin - which is preferably prepared by use of recombinant DNA techniques - is of benefit as it allows proteins such as whey and milk proteins (such as casein) to be stable in acidic solutions. This is of importance for the drinks market, such as skimmed milk, fruit juices and whey protein drinks, wherein before it was only possible to retain the flavour of the key proteins under fairly high acidic
10 conditions - such as pH 4.2 - if high amounts of stabiliser were present.

We have now found that for some applications small amounts of the de-esterified pectin prepared by the process of the present invention can be employed. At these low levels, the de-esterified pectin according to the present invention not only acts as a stabiliser but also
15 it does not have an adverse effect on the final product.

If desired, the use of the de-esterified pectin of the present invention would enable food manufacturers to increase the pH of foods, such as drinks. In this regard, in some cases the less acidic nature of the drinks may make them more palatable for people, especially
20 infants. Thus, in contrast to the prior art processes, it is now possible to retain the flavour of those proteins at pH conditions higher than 4.2, such as up to pH 5.5 (such as pH 5.2) by use of the block-wise enzymatically de-esterified pectin, particularly the block-wise enzymatically de-esterified pectin prepared by use of, for example, recombinant DNA techniques.

25 In addition, it is believed that even under low pH conditions, such as pH 4.2 or less, the block-wise enzymatically de-esterified pectin - particularly the block-wise enzymatically de-esterified pectin (preferably prepared by use of recombinant DNA techniques) - stabilises the protein(s) more than the prior art stabilisers that are used for those pH
30 conditions.

A further advantage is that the PME of the present invention is capable of producing a substantially homogeneous block-wise de-esterified pectin. By this we mean that substantially all of the pectin chains comprise at least two adjacent de-esterified carboxyl groups. However, for some applications it may not be necessary to prepare or use such a substantially homogeneous block-wise de-esterified pectin.

Without wishing to be bound by theory it is believed that the block-wise enzymatically de-esterified pectin - particularly that prepared by use of recombinant DNA techniques - stabilises the protein(s) by surrounding the protein(s) in a blanket of negative charges, thus forming a stable entity.

The PME enzyme of the present invention is useful for blockwise de-esterifying pectins when the pectins are contacted with the enzyme in a substantially aqueous medium. In some instances, de-esterifying pectins can increase the calcium ion sensitivity of a pectin - which in turn may be advantageous.

Alternatively, the PME enzyme of the present invention is useful for esterifying pectins when the pectins are contacted with the enzyme in a substantially non-aqueous medium, such as in the presence of methanol or in the presence of high concentrations of ammonium sulphate. This aspect is advantageous if, for example, it is desirable to reduce the calcium sensitivity of a pectin.

This method of esterifying pectins is advantageous because it obviates the need for the high temperature and methanol esterification conditions associated with the prior art processes. Thus, the present invention also includes the use of that esterified pectin in the preparation of a foodstuff, as well as the pectin *per se*.

In accordance with the present invention, the de-esterified pectin of the present invention is advantageous for the preparation of a foodstuff.

Preferably, the foodstuff is food for human and/or animal consumption. Typical preferred foodstuffs include jams, marmalades, jellies, dairy products (such as milk or cheese), meat products, poultry products, fish products and bakery products. The foodstuff may even be a beverage. The beverage can be a drinking yoghurt, a fruit juice or a beverage comprising whey protein.

In addition to the foodstuff comprising the PME treated pectin, the foodstuff may comprise more other components, such as one or more suitable food ingredients. Typical food ingredients include any one or more of an acid - such as citric acid - or a sugar - such as sucrose, glucose or invert sugar - or fruit - or other enzymes, preservatives, colourings and other suitable components.

In one preferred embodiment, the foodstuff of the present invention comprises fruit. Here, fruit imparts taste, colour and structure to the gel, as well as pectin, acid and a small amount of solids. Depending on the level of natural flavour and colour in the fruit, fruit dosages are normally from 25% to 60% of the jam. The solids content of ordinary fruit is around 10% Brix, but fruit concentrate, which is typically 65-70% Brix, can also be used. The pH in fruit varies widely, depending on the fruit in question, but most fruits have a pH between 3.0 and 3.5.

The pectin content also varies, depending on the fruit in question. For example, redcurrants, blackcurrants and oranges have a high pectin content, and satisfactory gels from these fruits can be obtained by adding only a small amount of extra pectin. The choice of pectin depends on the type of jam in question. For example, GRINDSTEDTM Pectin SS 200 is used in jams containing no fruit pieces or jam containing only very small fruit pieces. Fruit separation in such jams is not a problem, and consequently a slow-setting pectin and lower filling temperature can be used.

By way of example, GRINDSTEDTM Pectin RS 400 is used in jams containing large fruit pieces or whole fruit, for instance cherries or strawberries. In jams containing whole fruit it may be difficult to avoid fruit separation, and it is therefore necessary to use a rapid-set pectin such as GRINDSTEDTM Pectin RS 400.

5

The choice of pectin type may also depend on the container size in question. When standard jars are used, the filling temperature is less critical with regard to the stability of pectin, as the jars will cool down relatively quickly after filling and the pectin will not degrade. However, if the jam is filled into large containers, eg 500 or 1,000 kg, the cooling time will be very long. In the centre of such a large container the pectin will be especially subject to degradation, and the gel will be weaker at the centre than at the sides.

10

Consequently, a more slow-setting pectin is generally used for large containers, allowing filling at lower temperatures and thereby avoiding degradation of the pectin.

15

Sugar is added to jam for various reasons, such as:

1. To provide soluble solids - HE pectins can require a minimum soluble solids content of 55% before they will gel
2. To provide sweetness
- 20 3. To provide increased physical, chemical and microbiological stability
4. To provide an improved mouthfeel
5. To provide improved colour and gloss

20

Sucrose is the sugar normally used, but other sugars may well be used depending on the taste, sweetening effect, crystallisation or structure required. Price may also influence which type of sugar is used.

25

Invert sugar has the same sweetening effect as sucrose, whereas glucose syrup, glucose and sorbitol have a reduced sweetening effect. High fructose corn syrup and fructose will have a greater sweetening effect than sucrose.

30

The structure and strength of the gel as well as the gelling temperature will, to some extent, be influenced by changes in sugar composition.

5 Acid is added for two reasons: 1) partly to reduce the pH level to 3.0-3.2 to obtain a satisfactory gel with the pectin, and 2) partly to enhance the flavour of the fruit. The optimum pH for gelation using the HE pectins depends on the type of pectin and solids content in question.

10 If GRINDSTEDTM Pectin SS 200 is used in jam with 65-68% Brix, the optimum pH is 3.0-3.2. If the solids content is higher than this, the optimum pH is 3.1-3.3. Conversely, if the solids content is lower the optimum pH is 2.8-3.0. If GRINDSTEDTM Pectin RS 400 is used, the optimum pH is approximately 0.2 units higher than for GRINDSTEDTM Pectin SS 200.

15

The acid most commonly used is citric acid, monohydrate, in a 50% w/v solution.

Other acids (such as malic acid, tartaric acid or phosphoric acid) may be used but must always be in solution.

20

The choice of acid depends on legislation, price, and the tartness of sweetness required in the finished product.

25

Citric acid imparts a relatively strong acid taste to the finished product, whereas malic acid results in a softer but longer-lasting taste.

Tartaric acid may result in a slightly bitter taste, and phosphoric acid results in a sweeter taste.

Enzymatically treated pectin can prevent syneresis which can often occur in the manufacture of marmalades and jams with low soluble solids contents.

5 In some instances, the de-esterified pectin of the present invention is also advantageous for use as a stabiliser and/or viscosity modifier in the preparation of pharmaceuticals, pharmaceutical appliances, cosmetics and cosmetic appliances.

10 Preferably the block-wise enzymatically de-esterified pectin is a high ester pectin containing about 80% ester groups or less (i.e. a degree of esterification (DE) of 80% or less), preferably about 75% ester groups or less (i.e. a DE of about 75% or less). In this regard, the ratio of free carboxyl groups to esterified carboxyl groups on the pectin is from 1:1 to 1:4, preferably from 1:2 to 1:3.

15 Preferably, the block-wise enzymatically de-esterified pectin contains about 78% ester groups.

20 A Protocol for determining the degree of esterification of the PME substrate may be found on page 58 of WO-A-97/03574 (the contents of which are incorporated herein by reference). For ease of reference, this Protocol is recited after the Examples Section.

A Protocol for determining calcium sensitivity may be found on page 57 of WO-A-97/03574 (the contents of which are incorporated herein by reference). For ease of reference, this Protocol is also recited after the Examples Section.

25 Preferably the block-wise enzymatically de-esterified pectin has a high molecular weight. Typically, the molecular weight is between from about 50 KD to about 150 KD.

30 Preferably the block-wise enzymatically de-esterified pectin is prepared by treating a pectin with a PME that de-esterifies two or more adjacent galacturonic acid residues of the pectin on at least substantially all of the pectin chains.

Preferably the PME is derived from a PME obtainable from a micro-organism, preferably a bacterium.

5 The term "derived from a PME obtainable from a micro-organism" means that the PME has a sequence similar to that of a PME that is obtainable from a micro-organism, providing the PME can de-esterify pectin in a block-wise manner.

10 The term "derived from a PME obtainable from a bacterium" means that the PME has a sequence similar to that of a PME that is obtainable from a bacterium, providing the PME can de-esterify pectin in a block-wise manner.

15 The term "pectin" includes pectin in its normal sense, as well as fractions and derivatives thereof, as well as modified pectins (e.g. chemically modified pectins and enzymatically modified pectins).

20 By way of example, the pectin can be a derivatised pectin, a degraded (such as partially degraded) pectin or a modified pectin. An example of a modified pectin is pectin that has been prior treated with an enzyme such as a PME - which may be the same as the PME of the present invention or a different PME or a combination thereof. An example of a pectin derivative is pectin that has been chemically treated - eg. amidated.

25 Preferably, the pectin is not a pectin that has been prior treated with the enzyme polygalacturonase to substantially reduce the length of the pectin backbone.

As indicated, in a preferred aspect, the present invention encompasses variants, homologues and derivatives of the sequences presented herein. The present invention also encompasses fragments of such sequences.

The terms "variant", "homologue" or "fragment" in relation to the recombinant enzyme of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant amino acid sequence has PME activity, preferably having at least the same activity of a recombinant enzyme comprising sequence shown as SEQ I.D. No. 2. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant recombinant enzyme has PME activity. With respect to sequence homology (i.e. similarity), preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to the sequence shown in the attached sequence listings. More preferably there is at least 95%, more preferably at least 98%, homology to the sequence shown in the attached sequence listings.

Thus, enzymes of the present invention may also be modified to contain one or more (e.g. at least 2, 3, 5, or 10) substitutions, deletions or insertions, including conserved substitutions.

By way of example, conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

As indicated above, proteins of the invention are typically made by recombinant means, for example as described herein, and/or by using synthetic means using techniques well known to skilled persons such as solid phase synthesis. Variants and derivatives of such sequences include fusion proteins, wherein the fusion proteins comprise at least the amino acid sequence of the present invention being linked (directly or indirectly) to another amino acid sequence. These other amino acid sequences - which are sometimes referred to as fusion protein partners - will typically impart a favourable functionality - such as to aid extraction and purification of the amino acid sequence of the present invention. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and β -galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of the present invention so as to allow removal of the latter. Preferably the fusion protein partner will not hinder the function of the protein of the present invention.

In one aspect, the variant, homologue, derivative, or fragment of the amino acid sequence according to the present invention may comprise at least the following domain - which we have presented as Formula (I):

A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22 (I)

wherein

A1 is a hydrophobic or polar amino acid or a neutral amino acid

A2 is a hydrophobic amino acid

A3 is a hydrophobic amino acid

A4 is a polar amino acid

A5 is a polar or charged amino acid or neutral amino acid

A6 is a polar amino acid

A7 is a polar or charged or hydrophobic amino acid

A8 is a hydrophobic amino acid

A9 is a hydrophobic or polar amino acid

A10 is a hydrophobic or polar amino acid

5 A11 is a charged amino acid

A12 is a charged or polar or hydrophobic amino acid

A13 is a hydrophobic or charged amino acid or neutral amino acid

A14 is a hydrophobic or polar amino acid or charged or neutral amino acid

A15 is a charged or polar or hydrophobic amino acid

10 A16 is a polar or hydrophobic or charged amino acid or neutral amino acid

A17 is a polar or charged amino acid or neutral amino acid

A18 is a polar or charged or hydrophobic amino acid

A19 is a polar amino acid or a neutral amino acid

A20 is a hydrophobic or polar amino acid

15 A21 is a hydrophobic amino acid

A22 is a polar or hydrophobic amino acid.

This domain is described in our earlier UK patent application No. 9910935.7 filed 11 May 1999.

20

In this aspect of the present invention, preferably, A1 is a hydrophobic amino acid.

Preferably A5 is a polar amino acid.

25 Preferably A7 is a polar amino acid.

Preferably A9 is a hydrophobic amino acid.

Preferably A10 is a hydrophobic amino acid.

30

Preferably A12 is a charged amino acid.

Preferably A13 is a hydrophobic amino acid.

5 Preferably A14 is a hydrophobic amino acid.

Preferably A15 is a charged amino acid.

10 Preferably A16 is a polar amino acid.

Preferably A17 is a polar amino acid.

Preferably A18 is a polar amino acid.

15 Preferably A20 is a hydrophobic amino acid.

Preferably A22 is a polar amino acid.

20 For the amino acid sequence of formula (I), preferable examples of hydrophobic amino acids may include: Ala (A), Val (V), Phe (F), Pro (P), Met (M), Ile (I), Leu (L).

For the amino acid sequence of formula (I), preferable examples of charged amino acids may include Asp (D), Glu (E), Lys (K), Arg (R).

25 For the amino acid sequence of formula (I), preferable examples of polar amino acids may include: Ser (S), Thr (T), Tyr (Y), His (H), Cys (C), Asn (N), Gln (Q), Trp (W).

For the amino acid sequence of formula (I), a preferable example of a neutral amino acid is glycine (G).

Preferably A1 is A, V, G or T.

Preferably A2 is V or L.

5 Preferably A3 is L, F or I.

Preferably A4 is Q.

Preferably A5 is N, D, K, G or S.

10

Preferably A6 is C or S.

Preferably A7 is D, Q, K, E, Y or L.

15 Preferably A8 is I, L or F.

Preferably A9 is H, N, V, M or L.

Preferably A10 is A, C, I, P, L, C or S.

20

Preferably A11 is R.

Preferably A12 is K, R, L, Q or Y.

25 Preferably A13 is P, G or R.

Preferably A14 is N, G, M, A, L, R or S.

Preferably A15 is S, K, E, P or D.

30

Preferably A16 G, Y, H, N, K or V.

Preferably A17 is Q, G or K.

5 Preferably A18 is K, Q, F, Y, T or S.

Preferably A19 is N, C or G.

Preferably A20 is M, L, I, T, V, H or N.

10

Preferably A21 is V or I.

Preferably A22 is T, L or S.

15 We also believe that the amino acid sequence should retain the amino acid of sequence presented as formula (II):

N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-H-H-N-H-N-N-N-N-N-N-N-N-N-N-N-N-N-H-N-
N-N-P-C-P-H-N-H-N-H-N-G-
20 N-N-C-N-H-H-G-N-N-N (II)

wherein

H independently represents a hydrophobic amino acid

25 C independently represents a charged amino acid

P independently represents a polar amino acid

G represents glycine

N independently represents glycine or a hydrophobic or charged or polar amino acid.

For the amino acid sequence of formula (II): examples of hydrophobic amino acids include: Ala (A), Val (V), Phe (F), Pro (P), Met (M), Ile (I), Leu (L); examples of charged amino acids include Asp (D), Glu (E), Lys (K), Arg (R); and examples of polar amino acids include: Ser (S), Thr (T), Tyr (Y), His (H), Cys (C), Asn (N), Gln (Q), Trp (W).

The terms "variant", "homologue" or "fragment" in relation to the nucleotide sequence coding for the recombinant enzyme of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence codes for a recombinant enzyme having PME activity, preferably having at least the same activity of a recombinant enzyme comprising the sequence shown as SEQ I.D. No. 2. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence codes for a recombinant enzyme having PME activity.

With respect to sequence homology (i.e. similarity), preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology. More preferably there is at least 95%, more preferably at least 98%, homology.

In a preferred aspect, the terms "variant", "homologue" or "fragment" in relation to the nucleotide sequence coding for the recombinant enzyme of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence sequence shown as SEQ I.D. No. 1 providing the resultant nucleotide sequence codes for a recombinant enzyme having PME activity, preferably having at least the same activity of a recombinant enzyme comprising the sequence shown as SEQ I.D. No. 2. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence codes for a recombinant enzyme having PME activity. With respect to sequence homology (i.e. similarity), preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology. More preferably there is at least 95%, more preferably at least 98%, homology.

The above terms are synonymous with allelic variations of the sequences.

5 As indicated above, the present invention concerns the sequence presented in the attached sequence listings, or a variant, derivative or homologue thereof.

Preferably, the variant, derivative or homologue can have at least 75% sequence homology (i.e. identity) with any one or more of the sequences presented.

10 In particular, the term "homology" as used herein may be equated with the term "identity".

Here, sequence homology can be determined by a simple "eyeball" comparison of any one or more of the sequences with another sequence to see if that other sequence has at
15 least 75% identity to the sequence(s).

Relative sequence homology (i.e. sequence identity) can also be determined by commercially available computer programs that can calculate % homology between two or more sequences. A typical example of such a computer program is CLUSTAL.

20 Sequence homology (or identity) may moreover be determined using any suitable homology algorithm, using for example default parameters. Advantageously, the BLAST algorithm is employed, with parameters set to default values. The BLAST algorithm is described in detail at http://www.ncbi.nih.gov/BLAST/blast_help.html, which is
25 incorporated herein by reference. The search parameters are defined as follows, and are advantageously set to the defined default parameters.

Advantageously, "substantial homology" when assessed by BLAST equates to sequences which match with an EXPECT value of at least about 7, preferably at least about 9 and

most preferably 10 or more. The default threshold for EXPECT in BLAST searching is usually 10.

5 BLAST (Basic Local Alignment Search Tool) is the heuristic search algorithm employed by the programs blastp, blastn, blastx, tblastn, and tblastx; these programs ascribe significance to their findings using the statistical methods of Karlin and Altschul (see http://www.ncbi.nih.gov/BLAST/blast_help.html) with a few enhancements. The BLAST programs were tailored for sequence similarity searching, for example to identify homologues to a query sequence. The programs are not generally useful for
10 motif-style searching. For a discussion of basic issues in similarity searching of sequence databases, see Altschul *et al* (1994) Nature Genetics 6:119-129.

The five BLAST programs available at <http://www.ncbi.nlm.nih.gov> perform the following tasks:

15

blastp compares an amino acid query sequence against a protein sequence database;

blastn compares a nucleotide query sequence against a nucleotide sequence database;

20

blastx compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database;

tblastn compares a protein query sequence against a nucleotide sequence database dynamically translated in all six reading frames (both strands).

25

tblastx compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

BLAST uses the following search parameters:

30

HISTOGRAM Display a histogram of scores for each search; default is yes. (See parameter H in the BLAST Manual).

5 DESCRIPTIONS Restricts the number of short descriptions of matching sequences reported to the number specified; default limit is 100 descriptions. (See parameter V in the manual page). See also EXPECT and CUTOFF.

10 ALIGNMENTS Restricts database sequences to the number specified for which high-scoring segment pairs (HSPs) are reported; the default limit is 50. If more database sequences than this happen to satisfy the statistical significance threshold for reporting (see EXPECT and CUTOFF below), only the matches ascribed the greatest statistical significance are reported. (See parameter B in the BLAST Manual).

15 EXPECT The statistical significance threshold for reporting matches against database sequences; the default value is 10, such that 10 matches are expected to be found merely by chance, according to the stochastic model of Karlin and Altschul (1990). If the statistical significance ascribed to a match is greater than the EXPECT threshold, the match will not be reported. Lower EXPECT thresholds are more stringent, leading to fewer chance matches being reported. Fractional values are acceptable. (See parameter E
20 in the BLAST Manual).

CUTOFF Cutoff score for reporting high-scoring segment pairs. The default value is calculated from the EXPECT value (see above). HSPs are reported for a database sequence only if the statistical significance ascribed to them is at least as high as would
25 be ascribed to a lone HSP having a score equal to the CUTOFF value. Higher CUTOFF values are more stringent, leading to fewer chance matches being reported. (See parameter S in the BLAST Manual). Typically, significance thresholds can be more intuitively managed using EXPECT.

MATRIX Specify an alternate scoring matrix for BLASTP, BLASTX, TBLASTN and TBLASTX. The default matrix is BLOSUM62 (Henikoff & Henikoff, 1992). The valid alternative choices include: PAM40, PAM120, PAM250 and IDENTITY. No alternate scoring matrices are available for BLASTN; specifying the MATRIX directive in BLASTN requests returns an error response.

STRAND Restrict a TBLASTN search to just the top or bottom strand of the database sequences; or restrict a BLASTN, BLASTX or TBLASTX search to just reading frames on the top or bottom strand of the query sequence.

FILTER Mask off segments of the query sequence that have low compositional complexity, as determined by the SEG program of Wootton & Federhen (1993) Computers and Chemistry 17:149-163, or segments consisting of short-periodicity internal repeats, as determined by the XNU program of Claverie & States (1993) Computers and Chemistry 17:191-201, or, for BLASTN, by the DUST program of Tatusov and Lipman (see <http://www.ncbi.nlm.nih.gov>). Filtering can eliminate statistically significant but biologically uninteresting reports from the blast output (e.g., hits against common acidic-, basic- or proline-rich regions), leaving the more biologically interesting regions of the query sequence available for specific matching against database sequences.

Low complexity sequence found by a filter program is substituted using the letter "N" in nucleotide sequence (e.g., "NNNNNNNNNNNNNN") and the letter "X" in protein sequences (e.g., "XXXXXXXXXX").

Filtering is only applied to the query sequence (or its translation products), not to database sequences. Default filtering is DUST for BLASTN, SEG for other programs.

It is not unusual for nothing at all to be masked by SEG, XNU, or both, when applied to sequences in SWISS-PROT, so filtering should not be expected to always yield an effect.

Furthermore, in some cases, sequences are masked in their entirety, indicating that the statistical significance of any matches reported against the unfiltered query sequence should be suspect.

- 5 NCBI-gi Causes NCBI gi identifiers to be shown in the output, in addition to the accession and/or locus name.

For some applications, preferably sequence comparisons are conducted using the simple BLAST search algorithm provided at <http://www.ncbi.nlm.nih.gov/BLAST>.

10

Should Gap Penalties be used when determining sequence identity, then preferably the following parameters are used:

FOR BLAST	
GAP OPEN	0
GAP EXTENSION	0

FOR CLUSTAL	DNA	PROTEIN	
WORD SIZE	2	1	K triple
GAP PENALTY	10	10	
GAP EXTENSION	0.1	0.1	

15

Other computer program methods to determine identify and similarity between the two sequences include but are not limited to the GCG program package (Devereux *et al* 1984 Nucleic Acids Research 12: 387 and FASTA (Atschul *et al* 1990 J Molec Biol 403-410).

20

The present invention also encompasses nucleotide sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof. If the

sequence is complementary to a fragment thereof then that sequence can be used a probe to identify similar coding sequences in other organisms etc.

5 The present invention also encompasses nucleotide sequences that are capable of hybridising to the sequences presented herein, or any derivative, fragment or derivative thereof.

10 The present invention also encompasses nucleotide sequences that are capable of hybridising to the sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof.

The term "complementary" also covers nucleotide sequences that can hybridise to the nucleotide sequences of the coding sequence.

15 The term "variant" also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences presented herein.

20 Preferably, the term "variant" encompasses sequences that are complementary to sequences that are capable of hybridising under stringent conditions (eg. 65°C and 0.1xSSC {1xSSC = 0.15 M NaCl, 0.015 Na₃ citrate pH 7.0}) to the nucleotide sequences presented herein.

25 The present invention also relates to nucleotide sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein).

The present invention also relates to nucleotide sequences that are complementary to sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein).

The term "hybridization" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs J (1994) Dictionary of Biotechnology, Stockton Press, New York NY) as well as the process of amplification as carried out in polymerase chain reaction technologies as described in
5 Dieffenbach CW and GS Dveksler (1995, PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview NY).

Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridizing to the nucleotide sequences presented herein under conditions
10 of intermediate to maximal stringency. Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego CA), and confer a defined "stringency" as explained below.

15 Maximum stringency typically occurs at about $T_m - 5^\circ\text{C}$ (5°C below the T_m of the probe); high stringency at about 5°C to 10°C below T_m ; intermediate stringency at about 10°C to 20°C below T_m ; and low stringency at about 20°C to 25°C below T_m . As will be understood by those of skill in the art, a maximum stringency hybridization can be
20 used to identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridization can be used to identify or detect similar or related polynucleotide sequences.

In a preferred aspect, the present invention covers nucleotide sequences that can hybridise
25 to the nucleotide sequence of the present invention under stringent conditions (e.g. 65°C and $0.1\times\text{SSC}$).

The term "nucleotide" in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA for the
30 coding sequence of the present invention.

The term "construct" - which is synonymous with terms such as "conjugate", "cassette" and "hybrid" - includes the nucleotide sequence according to the present invention or, the case of the combination of constructs, the GOI directly or indirectly attached to a promoter. An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the *Shl*-intron or the ADH intron, intermediate the promoter and the nucleotide sequence of the present invention or the GOI. The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. In each case, the terms do not cover the natural combination of the gene coding for the enzyme ordinarily associated with the wild type gene promoter and when they are both in their natural environment.

The construct may even contain or express a marker which allows for the selection of the genetic construct in, for example, a filamentous fungus, preferably of the genus *Aspergillus*, such as *Aspergillus niger*, or plants, such as potatoes, sugar beet etc., into which it has been transferred. Various markers exist which may be used, such as for example those encoding mannose-6-phosphate isomerase (especially for plants) or those markers that provide for antibiotic resistance - e.g. resistance to G418, hygromycin, bleomycin, kanamycin and gentamycin.

The term "vector" includes expression vectors and transformation vectors.

The term "expression vector" means a construct capable of *in vivo* or *in vitro* expression.

The term "transformation vector" means a construct capable of being transferred from one species to another - such as from an *E.coli* plasmid to a filamentous fungus, preferably of the genus *Aspergillus*. It may even be a construct capable of being transferred from an *E.coli* plasmid to an *Agrobacterium* to a plant.

The term "tissue" includes tissue *per se* and organ.

The term "organism" in relation to the present invention includes any organism that could comprise the nucleotide sequence coding for the recombinant enzyme according to the present invention and/or products obtained therefrom, wherein a promoter can allow
5 expression of the nucleotide sequence according to the present invention when present in the organism.

Preferably the organism is a filamentous fungus, preferably of the genus *Aspergillus*, more preferably *Aspergillus niger*.

10

The term "transgenic organism" in relation to the present invention includes any organism that comprises the nucleotide sequence coding for the recombinant enzyme according to the present invention and/or products obtained therefrom, wherein the promoter can allow expression of the nucleotide sequence according to the present invention within the
15 organism. Preferably the nucleotide sequence is incorporated in the genome of the organism.

Preferably the transgenic organism is a filamentous fungus, preferably of the genus *Aspergillus*, more preferably *Aspergillus niger*.

20

Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, a promoter, the nucleotide sequence coding for the recombinant enzyme according to the present invention, constructs according to the present invention (including combinations thereof), vectors according to the present
25 invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention or the products thereof.

The term "transgenic organism" does not cover the native nucleotide coding sequence according to the present invention in its natural environment when it is under the control of
30 its native promoter which is also in its natural environment. In addition, the present

invention does not cover the native enzyme according to the present invention when it is in its natural environment and when it has been expressed by its native nucleotide coding sequence which is also in its natural environment and when that nucleotide sequence is under the control of its native promoter which is also in its natural environment.

5

The transformed cell or organism could prepare acceptable quantities of the desired compound which would be easily retrievable from, the cell or organism.

10

Preferably the construct of the present invention comprises the nucleotide sequence of the present invention and a promoter.

The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site.

15

In one aspect, the nucleotide sequence according to the present invention is under the control of a promoter that may be a cell or tissue specific promoter. If, for example, the organism is a plant then the promoter can be one that affects expression of the nucleotide sequence in any one or more of tuber, stem, sprout, root and leaf tissues.

20

By way of example, the promoter for the nucleotide sequence of the present invention can be the α -Amy 1 promoter (otherwise known as the Amy 1 promoter, the Amy 637 promoter or the α -Amy 637 promoter) as described in our co-pending UK patent application No. 9421292.5 filed 21 October 1994. Alternatively, the promoter for the nucleotide sequence of the present invention can be the α -Amy 3 promoter (otherwise

25

known as the Amy 3 promoter, the Amy 351 promoter or the α -Amy 351 promoter) as described in our co-pending UK patent application No. 9421286.7 filed 21 October 1994.

30

The promoter could additionally include features to ensure or to increase expression in a suitable host. For example, the features can be conserved regions such as a Pribnow Box or a TATA box. The promoter may even contain other sequences to affect (such as to

maintain, enhance, decrease) the levels of expression of the nucleotide sequence of the present invention or, in the case of the combination of constructs, the GOI. For example, suitable other sequences include the *Shl*-intron or an ADH intron. Other sequences include inducible elements - such as temperature, chemical, light or stress inducible elements. Also, suitable elements to enhance transcription or translation may be present. An example of the latter element is the TMV 5' signal sequence (see Sleat Gene 217 [1987] 217-225; and Dawson Plant Mol. Biol. 23 [1993] 97).

In addition the present invention also encompasses combinations of promoters and/or nucleotide sequences coding for proteins or recombinant enzymes and/or elements.

The present invention also encompasses the use of promoters to express a nucleotide sequence coding for the recombinant enzyme according to the present invention or the GOI, wherein a part of the promoter is inactivated but wherein the promoter can still function as a promoter. Partial inactivation of a promoter in some instances is advantageous. In particular, with the Amy 351 promoter mentioned earlier it is possible to inactivate a part of it so that the partially inactivated promoter expresses the nucleotide of the present invention or a GOI in a more specific manner such as in just one specific tissue type or organ.

The term "inactivated" means partial inactivation in the sense that the expression pattern of the promoter is modified but wherein the partially inactivated promoter still functions as a promoter. However, as mentioned above, the modified promoter is capable of expressing the nucleotide of the present invention or a GOI in at least one (but not all) specific tissue of the original promoter. One such promoter is the Amy 351 promoter described above. Examples of partial inactivation include altering the folding pattern of the promoter sequence, or binding species to parts of the nucleotide sequence, so that a part of the nucleotide sequence is not recognised by, for example, RNA polymerase. Another, and preferable, way of partially inactivating the promoter is to truncate it to form fragments thereof. Another way would be to mutate at least a part of the sequence so that the RNA

polymerase can not bind to that part or another part. Another modification is to mutate the binding sites for regulatory proteins for example the CreA protein known from filamentous fungi to exert carbon catabolite repression, and thus abolish the catabolite repression of the native promoter.

5

The term "GOI" with reference to the combination of constructs according to the present invention means any gene of interest. A GOI can be any nucleotide that is either foreign or natural to the organism (e.g. filamentous fungus, preferably of the genus *Aspergillus*, or a plant) in question. Typical examples of a GOI include genes encoding for proteins and enzymes that modify metabolic and catabolic processes. The GOI may code for an agent for introducing or increasing pathogen resistance. The GOI may even be an antisense construct for modifying the expression of natural transcripts present in the relevant tissues.

10

The GOI may even code for a non-native protein of a filamentous fungus, preferably of the genus *Aspergillus*, or a compound that is of benefit to animals or humans.

15

Examples of GOIs include other pectinases, galactonases, pectin depolymerases, polygalacturonases, pectate lyases, pectin lyases, rhamno-galacturonases, hemicellulases, endo- β -glucanases, arabinases, or acetyl esterases, or combinations thereof, as well as antisense sequences thereof.

20

These other types of enzymes can be added at the same time as the PME or, alternatively, prior to or after the addition of the PME.

By way of example, the GOI can be a PME as disclosed in WO-A-97/03574 or the PME disclosed in either WO-A-94/25575 or WO-A-97/31102 as well as variants, derivatives or homologues of the sequences disclosed in those patent applications.

25

The GOI may be a protein giving nutritional value to a food or crop. Typical examples include plant proteins that can inhibit the formation of anti-nutritive factors and plant proteins that have a more desirable amino acid composition (e.g. a higher lysine content

30

than a non-transgenic plant). The GOI may even code for an enzyme that can be used in food processing such as chymosin, thaumatin and α -galactosidase. The GOI can be a gene encoding for any one of a pest toxin, an antisense transcript such as that for patatin or α -amylase, ADP-glucose pyrophosphorylase (e.g. see EP-A-0455316), a protease antisense, a glucanase or genomic PME.

The GOI may even code for an intron of a particular enzyme but wherein the intron can be in sense or antisense orientation. In the latter instance, the particular enzyme could be genomic PME. Antisense expression of genomic exon or intron sequences as the GOI would mean that the natural PME expression would be reduced or eliminated but wherein the recombinant PME expression would not be affected. This is particularly true for antisense intron or sense intron expression.

The GOI can be the nucleotide sequence coding for the α -amylase enzyme which is the subject of our co-pending UK patent application 9413439.2 filed on 4 July 1994. The GOI can be the nucleotide sequence coding for the α -amylase enzyme which is the subject of our co-pending UK patent application 9421290.9 filed on 21 October 1994. The GOI can be any of the nucleotide sequences coding for the ADP-glucose pyrophosphorylase enzymes which are the subject of our co-pending PCT patent application PCT/EP94/01082 filed 7 April 1994. The GOI can be any of the nucleotide sequences coding for the α -glucan lyase enzyme which are described in our co-pending PCT patent application PCT/EP94/03397 filed 15 October 1994.

The host organism can be a prokaryotic or a eukaryotic organism. Examples of suitable prokaryotic hosts include *E. coli* and *Bacillus subtilis*. Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook *et al* (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press). If a prokaryotic host is used then the gene may need to be suitably modified before transformation - such as by removal of introns.

As mentioned above, a preferred host organism is of the genus *Aspergillus*, such as *Aspergillus niger*.

A transgenic *Aspergillus* according to the present invention can be prepared by following the teachings of Rambosek, J. and Leach, J. 1987 (Recombinant DNA in filamentous fungi: Progress and Prospects. CRC Crit. Rev. Biotechnol. 6:357-393), Davis R.W. 1994 (Heterologous gene expression and protein secretion in *Aspergillus*. In: Martinelli S.D., Kinghorn J.R.(Editors) *Aspergillus: 50 years on*. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp 525-560), Ballance, D.J. 1991 (Transformation systems for Filamentous Fungi and an Overview of Fungal Gene structure. In: Leong, S.A., Berka R.M. (Editors) Molecular Industrial Mycology. Systems and Applications for Filamentous Fungi. Marcel Dekker Inc. New York 1991. pp 1-29) and Turner G. 1994 (Vectors for genetic manipulation. In: Martinelli S.D., Kinghorn J.R.(Editors) *Aspergillus: 50 years on*. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp. 641-666). However, the following commentary provides a summary of those teachings for producing transgenic *Aspergillus* according to the present invention.

For almost a century, filamentous fungi have been widely used in many types of industry for the production of organic compounds and enzymes. For example, traditional Japanese koji and soy fermentations have used *Aspergillus sp.* Also, in this century *Aspergillus niger* has been used for production of organic acids particular citric acid and for production of various enzymes for use in industry.

There are two major reasons why filamentous fungi have been so widely used in industry. First filamentous fungi can produce high amounts of extracellular products, for example enzymes and organic compounds such as antibiotics or organic acids. Second filamentous fungi can grow on low cost substrates such as grains, bran, beet pulp etc. The same reasons have made filamentous fungi attractive organisms as hosts for heterologous expression according to the present invention.

In order to prepare the transgenic *Aspergillus*, expression constructs are prepared by inserting the nucleotide sequence according to the present invention (or even the GOI) into a construct designed for expression in filamentous fungi.

5 Several types of constructs used for heterologous expression have been developed. These constructs preferably contain a promoter which is active in fungi. Examples of promoters include a fungal promoter for a highly expressed extracellular enzyme, such as the glucoamylase promoter or the α -amylase promoter. The nucleotide sequence according to the present invention (or even the GOI) can be fused to a signal sequence which directs the
10 protein encoded by the nucleotide sequence according to the present invention (or even the GOI) to be secreted. Usually a signal sequence of fungal origin is used. A terminator active in fungi ends the expression system.

Another type of expression system has been developed in fungi where the nucleotide
15 sequence according to the present invention (or even the GOI) can be fused to a smaller or a larger part of a fungal gene encoding a stable protein. This can stabilize the protein encoded by the nucleotide sequence according to the present invention (or even the GOI). In such a system a cleavage site, recognized by a specific protease, can be introduced between the fungal protein and the protein encoded by the nucleotide sequence according to
20 the present invention (or even the GOI), so the produced fusion protein can be cleaved at this position by the specific protease thus liberating the protein encoded by the nucleotide sequence according to the present invention (or even the GOI). By way of example, one can introduce a site which is recognized by a KEX-2 like peptidase found in at least some *Aspergilli*. Such a fusion leads to cleavage *in vivo* resulting in protection of the expressed
25 product and not a larger fusion protein.

Heterologous expression in *Aspergillus* has been reported for several genes coding for bacterial, fungal, vertebrate and plant proteins. The proteins can be deposited intracellularly if the nucleotide sequence according to the present invention (or even the GOI) is not fused to
30 a signal sequence. Such proteins will accumulate in the cytoplasm and will usually not be

glycosylated which can be an advantage for some bacterial proteins. If the nucleotide sequence according to the present invention (or even the GOI) is equipped with a signal sequence the protein will accumulate extracellularly.

5 With regard to product stability and host strain modifications, some heterologous proteins are not very stable when they are secreted into the culture fluid of fungi. Most fungi produce several extracellular proteases which degrade heterologous proteins. To avoid this problem special fungal strains with reduced protease production have been used as host for heterologous production.

10

For the transformation of filamentous fungi, several transformation protocols have been developed for many filamentous fungi (Ballance 1991, *ibid*). Many of them are based on preparation of protoplasts and introduction of DNA into the protoplasts using PEG and Ca^{2+} ions. The transformed protoplasts then regenerate and the transformed fungi are
15 selected using various selective markers. Among the markers used for transformation are a number of auxotrophic markers such as *argB*, *trpC*, *niaD* and *pyrG*, antibiotic resistance markers such as benomyl resistance, hygromycin resistance and phleomycin resistance. A commonly used transformation marker is the *amdS* gene of *A. nidulans* which in high copy number allows the fungus to grow with acrylamide as the sole nitrogen source.

20

In another embodiment the transgenic organism can be a yeast. In this regard, yeast have also been widely used as a vehicle for heterologous gene expression. The species *Saccharomyces cerevisiae* has a long history of industrial use, including its use for heterologous gene expression. Expression of heterologous genes in *Saccharomyces*
25 *cerevisiae* has been reviewed by Goodey *et al* (1987, Yeast Biotechnology, D R Berry *et al*, eds, pp 401-429, Allen and Unwin, London) and by King *et al* (1989, Molecular and Cell Biology of Yeasts, E F Walton and G T Yarronton, eds, pp 107-133, Blackie, Glasgow).

For several reasons *Saccharomyces cerevisiae* is well suited for heterologous gene expression. First, it is non-pathogenic to humans and it is incapable of producing certain endotoxins. Second, it has a long history of safe use following centuries of commercial exploitation for various purposes. This has led to wide public acceptability. Third, the
5 extensive commercial use and research devoted to the organism has resulted in a wealth of knowledge about the genetics and physiology as well as large-scale fermentation characteristics of *Saccharomyces cerevisiae*.

A review of the principles of heterologous gene expression in *Saccharomyces cerevisiae*
10 and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes", Yeasts, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).

Several types of yeast vectors are available, including integrative vectors, which require
15 recombination with the host genome for their maintenance, and autonomously replicating plasmid vectors.

In order to prepare the transgenic *Saccharomyces*, expression constructs are prepared by inserting the nucleotide sequence of the present invention into a construct designed for
20 expression in yeast. Several types of constructs used for heterologous expression have been developed. The constructs contain a promoter active in yeast fused to the nucleotide sequence of the present invention, usually a promoter of yeast origin, such as the GAL1 promoter, is used. Usually a signal sequence of yeast origin, such as the sequence encoding the SUC2 signal peptide, is used. A terminator active in yeast ends the
25 expression system.

For the transformation of yeast several transformation protocols have been developed. For example, a transgenic *Saccharomyces* according to the present invention can be prepared by following the teachings of Hinnen *et al* (1978, Proceedings of the National Academy of

Sciences of the USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H *et al* (1983, J Bacteriology 153, 163-168).

The transformed yeast cells are selected using various selective markers. Among the
5 markers used for transformation are a number of auxotrophic markers such as LEU2, HIS4
and TRP1, and dominant antibiotic resistance markers such as aminoglycoside antibiotic
markers, eg G418.

Another host organism is a plant.

10 Even though the enzyme and the nucleotide sequence coding therefor are not disclosed in
EP-B-0470145 and CA-A-2006454, those two documents do provide some useful
background commentary on the types of techniques that may be employed to prepare
transgenic plants according to the present invention. Some of these background teachings
15 are now included in the following commentary.

The basic principle in the construction of genetically modified plants is to insert genetic
information in the plant genome so as to obtain a stable maintenance of the inserted genetic
material.

20 Several techniques exist for inserting the genetic information, the two main principles
being direct introduction of the genetic information and introduction of the genetic
information by use of a vector system. A review of the general techniques may be found
in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and
25 Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).

Thus, in one aspect, the present invention relates to a vector system which carries a
nucleotide sequence or construct according to the present invention and which is capable of
introducing the nucleotide sequence or construct into the genome of an organism, such as a
30 plant.

The vector system may comprise one vector, but it can comprise two vectors. In the case of two vectors, the vector system is normally referred to as a binary vector system. Binary vector systems are described in further detail in Gynheung An et al. (1980), Binary Vectors, *Plant Molecular Biology Manual A3*, 1-19.

One extensively employed system for transformation of plant cells with a given promoter or nucleotide sequence or construct is based on the use of a Ti plasmid from *Agrobacterium tumefaciens* or a Ri plasmid from *Agrobacterium rhizogenes* An et al. (1986), *Plant Physiol.* 81, 301-305 and Butcher D.N. et al. (1980), *Tissue Culture Methods for Plant Pathologists*, eds.: D.S. Ingrams and J.P. Helgeson, 203-208.

Several different Ti and Ri plasmids have been constructed which are suitable for the construction of the plant or plant cell constructs described above. A non-limiting example of such a Ti plasmid is pGV3850.

The nucleotide sequence or construct of the present invention should preferably be inserted into the Ti-plasmid between the terminal sequences of the T-DNA or adjacent a T-DNA sequence so as to avoid disruption of the sequences immediately surrounding the T-DNA borders, as at least one of these regions appear to be essential for insertion of modified T-DNA into the plant genome.

As will be understood from the above explanation, if the organism is a plant, then the vector system of the present invention is preferably one which contains the sequences necessary to infect the plant (e.g. the *vir* region) and at least one border part of a T-DNA sequence, the border part being located on the same vector as the genetic construct. Preferably, the vector system is an *Agrobacterium tumefaciens* Ti-plasmid or an *Agrobacterium rhizogenes* Ri-plasmid or a derivative thereof, as these plasmids are well-known and widely employed in the construction of transgenic plants, many vector systems exist which are based on these plasmids or derivatives thereof.

In the construction of a transgenic plant the nucleotide sequence or construct of the present invention may be first constructed in a microorganism in which the vector can replicate and which is easy to manipulate before insertion into the plant. An example of a useful
5 microorganism is *E. coli.*, but other microorganisms having the above properties may be used. When a vector of a vector system as defined above has been constructed in *E. coli.* it is transferred, if necessary, into a suitable *Agrobacterium* strain, e.g. *Agrobacterium tumefaciens*. The Ti-plasmid harbouring the nucleotide sequence or construct of the invention is thus preferably transferred into a suitable *Agrobacterium* strain, e.g. *A.*
10 *tumefaciens*, so as to obtain an *Agrobacterium* cell harbouring the nucleotide sequence or construct of the invention, which DNA is subsequently transferred into the plant cell to be modified.

As reported in CA-A-2006454, a large amount of cloning vectors are available which
15 contain a replication system in *E. coli* and a marker which allows a selection of the transformed cells. The vectors contain for example pBR 322, the pUC series, the M13 mp series, pACYC 184 etc.

In this way, the nucleotide or construct of the present invention can be introduced into a
20 suitable restriction position in the vector. The contained plasmid is used for the transformation in *E.coli*. The *E.coli* cells are cultivated in a suitable nutrient medium and then harvested and lysed. The plasmid is then recovered. As a method of analysis there is generally used sequence analysis, restriction analysis, electrophoresis and further biochemical-molecular biological methods. After each manipulation, the used DNA
25 sequence can be restricted and connected with the next DNA sequence. Each sequence can be cloned in the same or different plasmid.

After each introduction method of the desired promoter or construct or nucleotide sequence according to the present invention in the plants the presence and/or insertion of further
30 DNA sequences may be necessary. If, for example, for the transformation the Ti- or Ri-

plasmid of the plant cells is used, at least the right boundary and often however the right and the left boundary of the Ti- and Ri-plasmid T-DNA, as flanking areas of the introduced genes, can be connected. The use of T-DNA for the transformation of plant cells has been intensively studied and is described in EP-A-120516; Hoekema, in: The
5 Binary Plant Vector System Offset-drukkerij Kanthers B.B., Alblaserdam, 1985, Chapter V; Fraley, *et al.*, Crit. Rev. Plant Sci., 4:1-46; and An et al., EMBO J. (1985) 4:277-284.

Direct infection of plant tissues by *Agrobacterium* is a simple technique which has been widely employed and which is described in Butcher D.N. et al. (1980), *Tissue Culture*
10 *Methods for Plant Pathologists*, eds.: D.S. Ingrams and J.P. Helgeson, 203-208. For further teachings on this topic see Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27). With this technique, infection of a plant may be done on a certain part or tissue of the plant, i.e. on a part of a leaf, a root, a stem or another part of the plant.

15 Typically, with direct infection of plant tissues by *Agrobacterium* carrying the promoter and/or the GOI, a plant to be infected is wounded, e.g. by cutting the plant with a razor or puncturing the plant with a needle or rubbing the plant with an abrasive. The wound is then inoculated with the *Agrobacterium*. The inoculated plant or plant part is then grown
20 on a suitable culture medium and allowed to develop into mature plants.

When plant cells are constructed, these cells may be grown and maintained in accordance with well-known tissue culturing methods such as by culturing the cells in a suitable culture medium supplied with the necessary growth factors such as amino acids, plant
25 hormones, vitamins, etc. Regeneration of the transformed cells into genetically modified plants may be accomplished using known methods for the regeneration of plants from cell or tissue cultures, for example by selecting transformed shoots using an antibiotic and by subculturing the shoots on a medium containing the appropriate nutrients, plant hormones, etc.

Further teachings on plant transformation may be found in EP-A-0449375.

The process of the present invention can occur *ex vivo* or even *in vivo* - such as *in planta*.

In the latter respect, the plant may be a transgenic plant, such as a plant that has been genetically engineered to produce different levels and/or types of pectin. The plant may also be plant material, rather than a whole plant. Here, the plant material may be obtained from a transgenic plant, such as a plant that has been genetically engineered to produce different levels and/or types of pectin. The plant or plant material may be or may be derived from a vegetable, a fruit, or other type of pectin containing or producing plant.

Here, the vegetable material and/or the fruit material can be a mash.

In summation, the present invention provides a process for treating a pectin with a pectin methyl esterase (PME); wherein the PME is not a plant PME; but wherein the PME is capable of exhibiting at least one plant PME property; and wherein the at least one plant PME property comprises at least block-wise de-esterification of the pectin.

PME activity itself can be determined quite readily. A protocol for determining PME activity is presented after the Examples Section.

The purity of the PME fraction can be investigated by SDS-PAGE using Pharmacia PhastSystemTM with 10 - 15% SDS-gradient gels. Electrophoresis and silver staining of the proteins can be done as described by the manuals from Pharmacia. For determination of pI IEF 3-9 PhastSystemTM gels can be used.

Immuno gel electrophoresis can be used for characterisation of antibodies (see later section) - such as polyclonal antibodies - raised against PME. The enzyme fractions are then separated on SDS-PAGE and transferred to NC-paper by semi-dry blotting technique on a Semidry transfer unit of the PhastSystemTM. The NC-paper is incubated with the primer antibody diluted 1:50 and stained with the second antibody coupled to alkaline phosphatase (Dako A/S Glostrup, Denmark) used in a dilution of 1:1000.

Further studies that can be performed on the PME include peptide mapping. In this respect, PME can be digested with either trypsin or endo-proteinase Lys-C from *Lysobacter enzymogenes* (both enzyme preparations should be sequencing grade) - which can be purchased from Boehringer Mannheim, Germany.

Typically, 100 mg purified PME is carboxy methylated with iodoacetamide to protect the reduced SH-groups. Then the protein is cleaved with trypsin (4 mg/20-100 ml). The hydrolytic cleavage is performed at 40°C for 2 x 3 hrs. The reaction is stopped with addition of 20 ml TFA. After centrifugation at 15,000 rpm for 5 min the peptides are purified on a reverse-phase HPLC column (Vydac 10 C18 column). 2 x 500 ml samples are applied. The peptides are eluted and separated with an increasing acetonitrile gradient from 0.05 - 0.35% in 60 min in 0.1% TFA. The peptides are collected manually in Eppendorf tubes.

For digestion with endo-proteinase Lys-C, freeze dried PME (0.1 mg) is dissolved in 50 ml of 8 M urea, 0.4 M NH_4HCO_3 , pH 8.4. After overlay with N_2 and addition of 5 ml of 45 mM DTT, the protein is denatured and reduced for 15 min at 50°C under N_2 . After cooling to room temperature, 5 ml of 100 mM iodoacetamide is added for the cysteines to be derivatised for 15 min at room temperature in the dark under N_2 . Subsequently, 90 ml of water and 5 mg of endo-proteinase Lys-C in 50 ml 50 mM tricine and 10 mM EDTA, pH 8.0, are added and the digestion was carried out for 24 hrs at 37°C under N_2 .

The resulting peptides are then separated as described for trypsin digested peptides.

Selected peptides can be further purified on a Devosil 3 C_{18} RP-HPLC column 0.46x10 cm (Novo Nordisk, Denmark). The purified peptides are then applied on an amino acid sequencer, Applied Biosystems 476A, using pulsed-liquid fast cycles.

Antibodies can be raised against the enzyme of the present invention by injecting rabbits with the purified enzyme and isolating the immunoglobulins from antiserum according to procedures described according to N Harboe and A Ingild ("Immunization. Isolation of Immunoglobulins, Estimation of Antibody Titre" In A
 5 Manual of Quantitative Immuno-electrophoresis, Methods and Applications, N H Åxelsen, *et al* (eds.), Universitetsforlaget, Oslo, 1973) and by T G Cooper ("The Tools of Biochemistry", John Wiley & Sons, New York, 1977).

In another aspect the invention provides a process for treating a pectin with a pectin
 10 methyl esterase (PME) to produce a PME-treated high ester pectin comprising the step of contacting a pectin with an *Erwinia* PME wherein the PME results in block-wise de-esterification of the pectin.

In another aspect the invention provides a PME treated pectin prepared by the process
 15 as previously described.

In another aspect the invention provides a foodstuff comprising a PME treated pectin prepared by the protein as previously described.

20 In another aspect the invention provides use of a PME as previously described.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element,
 25 integer or step, or group of elements, integers or steps.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of
 30 these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.



The present invention will now be described only by way of example, in which reference is made to the following attached Figures:

Figure 1 – which is a representation of a plasmid;



5

Figure 2 – which is a representation of a plasmid;

Figure 3 – which is a representation of a plasmid;

10 Figure 4 - which is a representation of a plasmid; and

Figure 5 - which is a representation of a plasmid.



EXPERIMENTAL SECTION

Cloning of the *Erwinia chrysanthemi* PME gene.

5 Materials

Erwinia chrysanthemi (PD97) ("*E.chr.*") was purchased from Culture Collection of Plant Protection Service (PD) Wageningen, the Netherlands.

10 Growth of the *Erwinia* strain.

The strain was grown in LB- media at 30°C

DNA

15

Genomic DNA was isolated from the strain using Qiagen RNA/DNA kit (Qiagen).

PCR

20 Genomic DNA was used as template.

Primers to clone the PME gene from *Erwinia chrysanthemi* was designed from the published nucleotide sequence of the *Erwinia chrysanthemi* B374 PME gene, accessed from the EMBL/GenBank Data Libraries (accession number Y00549).

25

Erwinia chrysanthemi PCR primers

PME 5' end primer: 5'-AGTCGACGTGTATGTTAAAAACGATCTCTGG-3'

PME 3' end primer: 5'- AGCGGCCGCAATTCGTCAGGGTAATGTCGG-3'

30

The 5' end primers contain a *Sall* enzyme restriction site, which is written in italic and the 3' end primers contain a *NotI* enzyme restriction site, which is underlined, in order to facilitate cloning of the amplified gene into expression vectors.

- 5 PCR was performed with the Expand High Fidelity PCR system (Boehringer Mannheim) according to the manufactures instructions with the following temperature cycling:

95°C 3 min in 1 cycle

10 94°C 15 sec

50°C 30 sec

68°C 3 min in 10 cycles

94°C 15 sec

15 57°C 30 sec

68°C 3 min and additional 20 sec pr. cycle in 20 cycles

Cloning of PCR fragments

- 20 PCR fragments were cloned into the PCR 2.1-TOPO cloning vector (Invitrogen), as described by the manufacturer.

DNA sequencing.

- 25 Double stranded DNA was sequenced essentially according to the dideoxy method of Sanger *et al* (1979) using the Thermo Sequenase fluorescent labelled primer cycle sequencing kit with 7-deaza-dGTP (Amersham Pharmacia Biotech), 5'Cy5-labelled primers and the Pharmacia LKB A.L.F. DNA sequencer (Ref: Sanger, F., Nicklen, S., and Coulson A.R. (1979) DNA sequencing with chain-determinating inhibitors. Proc.

Nat. Acad. Sci. USA 74: 5463-5467). The primers used for sequencing are listed below, presented 5' to 3':

UNI (M13-20 primer) - 17mer

5 Cy5-GTAAACGACGGCCAGT

REV - 19mer

Cy5-GGAAACAGCTATGACCATG

10 *E. chr* PME. - 01 17mer

Cy5-GATTATCCATGCTGGTG

Erwinia chrysanthemi PME - 02 18mer

Cy5- CGGCGTCTATAATGAACG

15

Erwinia chrysanthemi PME - 03 16mer

Cy5-GCGACAGCGACAGCAG

Erwinia chrysanthemi PME - 04 19mer

20 Cy5-CCGTGGCAGCCGCAATGAC

The sequenced nucleotide sequence of the PME gene is shown in the attached sequence listings.

EXPRESSION OF THE *Erwinia chrysanthemi* PME GENE IN *E.coli*.

Generation of the expression vector pATP1:

- 5 pATP1 was generated by modifying the pQE60 expression vector from Qiagen in order to use the cloned genes own translation start site and to avoid the histidine tag. The pQE60 expression vector is shown in Figure 1.

- 10 The 64bp *EcoRI* - *HindIII* fragment was excised from the pQE60 expression vector and replaced with the 50bp *EcoRI* - *BamHI* fragment from the pSPORT1 vector (Gibco/BRL), to introduce more enzyme restriction sites.

50bp pSPORT1 *EcoRI* - *HindIII* fragment:

- 15 5' AAGCTTGGATCCTCTAGAGCGGCCGCCGACTAGTGAGCTCGTCGACCCGGG
AATTC 3'

The *EcoRI* enzyme restriction site is underlined and the *HindIII* enzyme restriction site is written in bold and italic letters.

20

The 10bp *EcoRI* - *SalI* fragment within the 50bp fragment obtained from the pSPORT1 vector, was replaced with a 28bp *EcoRI* - *SalI* fragment containing a Ribosome Binding Site (RBS) and thereby creating expression vector pATP1, see Figure 2.

- 25 Generation of the 28bp *EcoRI* - *SalI* fragment by annealing of two oligo nucleotides:

RBS primer 1

5' CACACAGAATTCATTAAGAGGAGAAATTAACCCGTCGACCCGGGAG 3'

RBS primer 2:

5'CTCCCGGGTCGACGGGTAAATTTCTCCTCTTTAATGAATTCTGTGTG 3'

EcoRI enzyme restriction site is underlined

5 *Sall* enzyme restriction site is written in italic letters

The Ribosome Binding Site (RBS) is written in bold letters

The cloned PME gene from *Erwinia chrysanthemi* was excised from the PCR2.1 TOPO vector at the *Sall* and *NotI* sites, located in the primers used to PCR clone the genes.

10 The *Sall*-*NotI* gene fragments were recloned into the pATP1 expression vector, pATP1*E.chr*.PME (Figure 3).

Transformation of pATP1*E.chr*.PME vector into M15/pREP4 competent cells.

15 The pATP1*E.chr*.PME vector was transformed into competent M15/pREP4 cells as described by the manufacturer (Qiagen).

Colonies containing the pATP1*E.chr*.PME vector were selected and used for induction of expression of the *Erwinia chrysanthemi* PME gene.

20

Growth of *E.coli*

25 *E.coli* transformed with pATP1*E.chr*PME vector was grown in LB-medium + 100 µg/ml ampicillin and 25 µg/ml kanamycin over night at 37 °C and 20 ml pre-culture was added to 800 ml LB-medium 100 µg/ml ampicillin and 25 µg/ml kanamycin and incubated at 37 °C. In total 3 x 800 ml was prepared. The cells were grown to the absorption at 600 nm was 0.7. 800 µl 1M IPTG was added and after 4 hrs incubation at 37 °C the cells were harvested.

Preparation of cell free extract

The cells were harvested by centrifugation at 10000 rpm for 10 min and resuspended in 50 ml extraction buffer (50 mM MES pH 6.8). The cells were disrupted by sonication
5 for 4 x 3 min with duty cycle of 70%. In between and during the sonication treatment the sample was stored on ice. The PME fraction (the supernatant) was obtained after centrifugation at 10000 rpm for 10 min.

Chromatography

10 The PME was purified according to the following procedure. All operations were performed at 4 °C. The supernatant obtained as described above was separated by cation exchange chromatography. A 50 ml sample was applied to a CM-Sepharose™CL-6B (50 ml column material) and washed with buffer A: 50 mM MES pH 6.8. The majority of the
15 proteins did not bind to the column but the PME was absorbed and after washing off the unbound proteins with buffer A the bound proteins were eluted with an increasing NaCl gradient from 0 - 1M NaCl in total 450 ml. The flow was 0.5 ml/min and fractions of 2.5 ml were collected. The protein absorption profile was measured at 280 nm.

20 All fractions were analysed for PME activity and protein. The protein content was measured spectrophotometrically with the BioRad method.

The fractions containing PME activity were pooled and used as enzyme extract for enzymatic PME treatment of pectin. SDS-PAGE revealed that this partially purified *E.*
25 *chrysanthemi* PME fraction only contained 3-4 proteins.

In order to purify the PME to homogeneity 1 ml of the pooled fraction was concentrated by dialysis using Centricon filter system. Buffer exchange to 50 mM Tris, 0.1M NaCl pH 7 was done on the same system.

200 µl concentrated sample was then applied to a Sephacryl™S-200 (2.6x 70 cm) gel filtration column. The column was equilibrated with 50 mM Tris, 0.1 M NaCl pH 7. The flow was 0.5 ml/min and fractions of 0.5 ml were collected.

5 The fractions containing PME activity were pooled and concentrated using Centricon as described above. The concentrated sample was then applied to a Superdex™ G-75 which was equilibrated with 50 mM Tris, 0.1 M NaCl pH 7. The flow was 0.5 ml/min and fractions of 2ml were collected. The fractions containing PME activity were pooled and concentrated.

10 Enzyme activity

PME catalyses the cleavage of methylester groups from pectin. During the purification steps PME was detected by a fast method using methyl red indicator test. Due to cleavage
15 of methyl groups from galacturonic residues in the pectin chain, carboxyl groups were formed and the pH drops in the assay. The pH indicator - methyl red - changes colour at pH drop from yellow (pH 6.2) to pink (pH 4.2). The assay contained 1 ml 0.5 % lime pectin (DE 70%) solubilized in 0.15 M NaCl pH 7 and 25 µl sample. The samples which showed positive methyl red test after 10 min incubation at 30°C were then further
20 measured by the titration method. (Versteeg et al. (1978) Lebensmittel.-Wiss. u. Technol., 11: 267-274)

With the titration method the assay contained 10 ml 0.5 % lime pectin solubilized in 0.15 M NaCl pH 6.8 and 10 - 100 µl sample. Titration was performed with 0.02 M NaOH and
25 the reaction was measured at room temperature. An automatic titrator was used. (Versteeg et al. (1978) Lebensmittel.-Wiss. u. Technol., 11: 267-274)

SDS-PAGE/Western blotting

30 The purity of the PME fraction was investigated by SDS-PAGE as discussed above.

Antibody production

Antibodies are raised against the enzyme of the present invention by injecting rabbits with
5 the purified enzyme and isolating the immunoglobulins from antiserum according to
procedures described according to N Harboe and A Ingild ("Immunization, Isolation of
Immunoglobulins, Estimation of Antibody Titre" In A Manual of Quantitative
Immuno-electrophoresis, Methods and Applications, N H Axelsen, *et al* (eds.),
Universitetsforlaget, Oslo, 1973) and by T G Cooper ("The Tools of Biochemistry", John
10 Wiley & Sons, New York, 1977).

STUDY EXPERIMENT 1

During purification of PME the cell free extract was applied to a cation exchange column
15 (CM-Sepharose CL-6B). PME binds strongly to a cation exchange column material at pH
6.8 whereas most of the proteins do not bind to the column and so elute in the wash
volume. With increasing NaCl gradient PME eluted into one peak (fraction 56-64).

After concentration the PME fraction was further purified using gel filtration chromatog-
20 raphy (Sephacryl S-200 column) and followed by Superdex G-75 gel filtration. Fractions
containing the highest PME activity were pooled. The enzyme activity was 65 U/ml.

The fraction was tested for pectin degrading activity by viscosity determination with 1%
pectin at pH 4.8. The results showed that after 24 hrs no change in the viscosity was
25 found.

SDS-PAGE showed only one protein band in the purified PME fraction with a MW of
36,000 D. Isoelectric focusing of PME showed that the pI was > 9.

Characterization and kinetic data

Characterization of PME and optima determinations were all done with the titration method as described in Materials and Methods.

5

pH optimum of PME activity was measured with 0.5% lime pectin in 0.15 M NaCl. The optimum was found around pH 7. The enzyme has pH optimum at neutral pH but at pH 5 70% of the maximal activity was still measured.

10

Temperature optimum was found at 48°C .

15

The temperature stability of PME was determined by incubating the enzyme sample in Eppendorf tubes at various temperatures for 15 min. After incubation the enzyme activity was measured by traditional assay by titric method. The stability of the enzyme activity was between 20°- 50°C. Incubation for 15 min at 60°C resulted in inactivation of the enzyme.

20

The affinity for lime pectin was determined by Hanes plot of different pectin concentration versus activity. The K_m was calculated from the curve to be 0.44 mg/ml. The K_m was determined with pectin with DE 70% and the results showed that the K_m value was in the same range as found for orange PME but was 10 times lower than found for fungal PME from *Aspergillus*. This means that the catalytic activity of the plant and bacteria enzymes are 10-fold higher than that of the fungal enzyme.

25

E. chrysanthemi PME could also de-esterify sugar beet pectin. The PME activity was measured as described in Materials and Methods except that 1% sugar beet pectin solubilized in 0.15 M NaCl was used in the assay.

We have also found that the enzyme does not necessarily require NaCl for activity. However, the activity is increased with addition of NaCl up to 0.1- 0.15 M NaCl. Higher concentrations of NaCl decreases the activity.

5 STUDY EXPERIMENT 2

PECTIN TREATED WITH *E. chrysanthemi* HAS SIMILAR PROPERTIES TO
PECTIN TREATED WITH PLANT PME

10 Calcium sensitive pectin

The URS pectin was treated with *E. chrysanthemi* PME and the obtained modified pectin was characterized with respect to %DE and Calcium sensitivity (CS).

	%DE	CS
GRINSTED™ URS Pectin	81.1%	1.1
Pectin 2084-124-1	73.7%	2.2
Pectin 2084-124-2	70.6%	14.5
Pectin 2084-125-2	66.6%	gel.
Pectin 2084-125-1	62.8%	gel.

15 The two pectins (Pectin 2084-125-2 and Pectin 2084-125-1) gelled with the added calcium in the test because of the very high Ca-sensitivity and it was therefore not possible to obtain a CS value. This very high Ca-sensitivity is only obtainable with block-wise de-methylated pectins.

20

Enzymatic fingerprinting of the *E. chrysanthemi* modified pectins by using pectin lyase or polygalacturonase showed that the *E. chrysanthemi* PME de-methylates pectin blockwise producing non polygalacturonic acid like blocks (random blocks).

Effect of *E. Chrysanthemi* PME treated pectin on the viscosity and stability of protein drinks

	%DE	SP in acidified milk drink	Viscosity at cP
2143-17.1	78.9%	0.15%	10.2
2143-27	77.5%	0.15%	10.6

5 SP = The minimum concentration at which the pectin stabilize the acidified milk drink.

De-esterification of the URS pectin from 81 % to 78 - 79 % changed the Ca-sensitivity.

10 The enzymatic modified pectins were tested in the acidified milk drink at the dosage concentrations of 0.1%, 0.15%, 0.175%, 0.2% and 0.25%. The quality of the individual acidified milk drink produced was investigated by the parameters such as whey separation, the sedimentation % and the viscosity.

15 The results showed that the enzymatic modified pectins stabilize the protein at the low pectin concentration of 0.15%. Each of the samples had a low viscosity. The *E. chrysanthemi* PME modified pectins have lower viscosity at the pectin concentration of 0.15% than the standard commercial stabilizer.

20 By treating the mother URS pectin with *E. chrysanthemi* PME an unsuitable pectin was made suitable as a stabilizing agent in the acidified milk drink and this treated pectin behave just as well as an excellent commercial stabilizer.

METHODS

Enzymatic treatment of pectin with PME from *E. chrysanthemi*

5 A batch of enzymated pectin was prepared as follows:

45 g pectin was dissolved in hot water under efficient stirring. 15 g NaCl was added and the volume adjusted to 1.8 l with water. This solution was stirred until the salt had dissolved. The pectin solution was cooled to 40 °C and the pH was increased to pH 6.5, using 1 N NaOH and efficient stirring. An appropriate sample of *E. chrysanthemi* PME was added and the enzymatic reaction continued until the desired degree of esterification was achieved. The pH was kept constant at pH 6.5 by automatic dosage of 1 N NaOH during the incubation period, and the enzymatic reaction was followed by the consumption of NaOH.

15

When the pectin sample had reached the desired degree of esterification the NaOH addition was stopped, the pH of the solution lowered to about 3.0 by addition of 2 % HCl. The pectin solution was then heated to 70 °C for 5 min to completely inactivate the enzyme. The treated pectin was precipitated with 1 volume of isopropanol, washed with 60% isopropanol and pressed to about 50 % dry matter. The treated pectin batch was then air dried at 40 °C and finally milled to a dry powder.

20

Determination of pectin samples calcium sensitivity index (CS)

25 Calcium sensitivity was measured by the protocol presented above.

Determination of pectin samples degree of esterification (%DE)

The degree of esterification was measured by the protocol presented above.

30

Acidified milk drink test

Standardised skimmed milk (17% MSNF), prepared from mixing powdered milk with adequate volume of de-ionised water at 68 °C for 20 minutes and cooled down to 30 °C, was acidified at 30 °C with 3.3% glucone-delta-lactone (GDL) to about pH 4. The pectin sample was added as a sugar solution and stirred for 30 min. The acidified milk drink was homogenized at 200 bar at room temperature and then filled into sterile 250 ml plastic bottles. It was then heated on a water bath at 75 °C for 10 min with intervals of shaking for 5 minutes. Finally, the drink was cooled to room temperature and then stored overnight at 5 °C.

Viscosity determination of the acidified milk drink

The viscosity of a sample of the milk drink was determined using a Brookfield Viscometer 11T at rpm 30. After stirring for 30sec the viscosity is measured.

Protein stability measured by a centrifugation test

40 g of a sample (e.g. acidified milk drink) is centrifuged at room temperature at 2300xg for 20 min. The supernatant is discarded and the centrifuge glass placed upside down for 30 min. The glass is weighed and the sedimentation % calculated as follows:

$$\% \text{ Sedimentation} = \frac{\text{Wgt of glass after centri} - \text{Wgt of glass}}{\text{Wgt of sample}} \times 100$$

Where Wgt= weight and centri= centrifugation

Construction of *Bacillus* expression plasmid pCS.

The *Bacillus/E.coli* shuttle vector pDP66K (obtained from Dr L. Dijkhuizen, Rijks University of Groningen, the Netherlands), was modified to make it suitable for cloning and expression of different genes. Details on the pDP66K vector are described in Penninga D *et al* (1996). (It is to be noted that any other suitable shuttle vector - such as a commercially available shuttle vector - could also be used in this experiment.) The pCS plasmid was generated by modifying the promoter, the cyclodextrin glycosyl transferase (cgt) signal sequence, deleting the rest of the cyclodextrin glycosyl transferase gene and replacing the transcription terminal sequence. The p32 promoter and cyclodextrin glycosyl transferase signal sequence was modified by PCR to contain a *NcoI* site at the ATG codon in the 3' end of the signal sequence. The transcription terminator sequence was replaced by a PCR amplified transcription terminator sequence from the pUB110 plasmid (McKenzie, T., Hoshino, T., Tanaka, T. and Sueoka, N. (1986) The nucleotide sequence of pUB110: some salient features in relation to replication and its regulation. *Plasmid* 15 (2), 93-103, and McKenzie, T., Hoshino, T., Tanaka, T. and Sueoka, N. (1987) Correction. A revision of the nucleotide sequence and functional map of pUB110. *Plasmid* 17 (1), 83-85). A 5' *BamHI* and a 3' *HindIII* enzyme restriction sites were introduced into the PCR amplified transcription terminator sequence for cloning purposes. The resultant pCS plasmid is shown in Figure 5.

Generation of the PME gene fragments for cloning into the *Bacillus* pCS plasmid.

Two PME gene PCR products were amplified, one containing the full length coding region where the second amino acid was changed from a leucine to a valine in order to introduce a *NcoI* site at the 5' ATG start codon of the gene for cloning purposes. In the 3' end a *BamHI* site was introduced for cloning purposes. The second PME gene PCR product was amplified without the genes signal sequence, starting from the alanine amino acid codon at position 25 at the amino acid level. The PCR product was designed to contain a methionine in front of the starting alanine amino acid in order to introduce a *NcoI*, necessary for cloning purposes. In the 3' end of the PCR product a *BamHI* site

was introduced. PCR amplification of the two PME sequences were verified by DNA sequencing. The two amplified PME sequences were cloned into the pHM plasmid using the *NcoI* and *BamHI* restriction enzymes while the PME sequence without the signal sequence also was cloned into the pCS plasmid using the same restriction enzymes.

Expression of the PME gene in *Bacillus*.

The four different constructs were transformed into *Bacillus subtilis* and cultured in 2 xYT media containing 50mg/ml kanamycin.

Expression of the *E. chrysanthemi* PME gene in *Aspergillus niger*.

Construction of the expression vector pPR42-FS-PMEA.

For expression in *Aspergillus niger* the *E. chrysanthemi* PME gene was furnished with a fungal signal sequence derived from the *Aspergillus niger* PME gene (Khanh, N.Q. et al (1991) Gene 1, 71-77) comprising the following sequence:

Aspergillus niger PME signal sequence:

ATGGTTAAGTCAATTCTTGCATCCGTTCTCTTTGCGGCGACTGCGCTGGCC

MetValLysSerIleLeuAlaSerValLeuPheAlaAlaThrAlaLeuAla

Three overlapping oligo nucleotide 5' end primers P1, P2 and P3 were used together with a 3' end primer P4 to fuse the fungal signal sequence to the 5' of the coding sequence of the *E. chrysanthemi* PME gene by PCR.

P1: 5'-GCGGCGACTGCGCTGGCCATGTTAAAAACGATCTCTGGAACCC

P2: 5'-AAGTCAATTCTTGCATCCGTTCTCTTTCGCGGCGACTGCGC

P3: 5'-TGAATTCTTCATGGTTAAGTCAATTCTTGCATCCG

P4: 5'-TACTAGTGTCAGGGTAATGTCGGC

5

The 5' end primer P1 contains the 5' end of the *E. chrysanthemi* PME coding sequence, underlined. The 5' end primer P3 contains an *EcoRI* restriction enzyme site, underlined, and the 3' end primer P4 contains a *SpeI* restriction enzyme site, underlined, to facilitate cloning.

10

PCR was performed with the Expand High Fidelity PCR system (Boehringer Mannheim) according to the instructions of the manufacturer.

15

The amplified DNA fragment containing the fungal signal sequence fused to the *E. chrysanthemi* PME gene was cloned into the PCR 2.1-TOPO cloning vector (Invitrogen) according to the instructions of the manufacturer. The cloned DNA fragment was sequenced using a Thermo Sequenase fluorescent cycle sequencing kit (Amersham) and an ALF DNA sequencer (Pharmacia) following the recommendations of the manufacturer.

20

An *EcoRI* DNA fragment containing the fungal signal sequence and the *E. chrysanthemi* PME gene was excised from the PCR 2.1-TOPO cloning vector, and introduced into the fungal expression vector pPR42 (See WO 9838321 A) containing the XlnB promoter and the TrpC terminator, generating the vector pPR42-FS-PMEA (Figure 4).

Transformation of *Aspergillus niger*.

The pPR42-FS-PMEA vector was transformed into an uridine auxotrophic mutant of *Aspergillus niger* using a protocol adapted from Van Someren et al (1991) Curr. Genet. 20, 293-299, using cotransformation with a *A. niger* orotidine-5'-phosphate-decarboxylase gene and selection for complementation of the uridine auxotrophic mutation (Goosen et al (1987) Curr. Genet. 11, 499-503).

For the purification of *Aspergillus niger* protoplasts, spores from a PDA (Potato Dextrose Agar-Difco Lab. Detroit) plate, containing 5 mM uridine, incubated for 3-4 days at 30°C are washed off in 10 ml ST (8 g/l NaCl, 0.5 g/l Tween 20). One million spores pr ml are inoculated in 200 ml growth medium in a 500 ml shaking flask.

The growth medium contains: 6 g/l NaNO₃, 1.5 g/l KH₂PO₄, 0.5 g/l MgSO₄·7H₂O, 0.5 g/l KCL, 10 mM (NH₄)₂SO₄, 0.2 % Casein enzymatic hydrolysate (Sigma C-0626), 2 % glucose, 0.5 % Yeast extract (Difco 0127-17-9), 10 mM Uridine, 10mg/l EDTA, 4.4 mg/l ZnSO₄·7H₂O, 1 mg/l MnCl₂·4H₂O, 0.32 mg/l CoCl₂·6H₂O, 0.32 mg/l CuSO₄·5H₂O, 0.22 mg/l (NH₄)₆Mo₇O₂₄·4H₂O, 1.47 mg/l CaCl₂·2H₂O, 1.0 mg/l FeSO₄·7H₂O, pH 6.0.

The flask is shaken at 230-250 rpm for 16-18 hours at 30°C. The mycelium is harvested using Miracloth and washed 2-3 times with SMC (1.33 M Sorbitol, 50 mM CaCl₂, 20 mM MES, pH 5.8). 1 g wet mycelium is resuspended in 20 ml of SMC containing 150 mg Lyzing enzyme (Sigma L-2265), in a sterile flask and incubated at 37°C, 80-100 rpm for 1-3 hours until protoplasts are released. The protoplasts are harvested by passing the suspension through 5 ml sterile glasswool followed by centrifugation at 3000 rpm for 10 min. The protoplasts are washed twice with 5-10 ml of STC (1.33 M Sorbitol, 50 mM CaCl₂, 10 mM Tris/HCl, pH 7.5) and finally resuspended in STC at 1 x10⁸ protoplasts/ml.

For the transformation, 0.2 ml of protoplasts are carefully mixed with 5-10 mg DNA (pPr42-FS-PMEA), 0.5 mg Selection DNA (pGW635 - containing the orotidine-5'-phosphate-decarboxylase gene(Goosen et al (1987) Curr. Genet. 11, 499-503)) and 50 ml PEG solution (0.25 g/ml PEG 6000, 50 mM CaCl₂, 10 mM Tris/HCl, pH 7.5). The mixture is incubated for 20 min. at room temperature after which 2 ml of PEG solution is carefully added and mixed. After further incubation for 5 min at room temperature 6 ml of STC is added, and the mixture is carefully shaken. The mixture is centrifuged at 300 rpm for 10 min, and most of the supernatant is removed.

The protoplasts are resuspended in the remaining 1-2 ml of supernatant, mixed with TR soft agar (6 g/l NaNO₃, 1.5 g/l KH₂PO₄, 0.5 g/l MgSO₄·7H₂O, 0.5 g/l KCL, 1.22 M Sorbitol, 10mg/l EDTA, 4.4 mg/l ZnSO₄·7H₂O, 1 mg/l MnCl₂·4H₂O, 0.32 mg/l CoCl₂·6H₂O, 0.32 mg/l CuSO₄·5H₂O, 0.22 mg/l (NH₄)₆Mo₇O₂₄·4H₂O, 1.47 mg/l CaCl₂·2H₂O, 1.0 mg/l FeSO₄·7H₂O, 0.8 % agar (Difco 0140-01), pH 6.0. and plated on TR plates (As TR soft agar but with 1.2 % agar). Transformed colonies are picked and replicated on fresh TR plates.

Growth of *A. niger* transformants for expression of the *E. chrysanthemi* PME gene.

For the expression of the *E. chrysanthemi* PME gene in *A. niger* transformants, spores (aprox 500,000 pr ml) are inoculated in induction medium (6 g/l NaNO₃, 1.5 g/l KH₂PO₄, 0.5 g/l MgSO₄·7H₂O, 0.5 g/l KCL, 10 mM (NH₄)₂SO₄, 10mg/l EDTA, 4.4 mg/l ZnSO₄·7H₂O, 1 mg/l MnCl₂·4H₂O, 0.32 mg/l CoCl₂·6H₂O, 0.32 mg/l CuSO₄·5H₂O, 0.22 mg/l (NH₄)₆Mo₇O₂₄·4H₂O, 1.47 mg/l CaCl₂·2H₂O, 1.0 mg/l FeSO₄·7H₂O, 29.4 g/l Na₃citrate·2H₂O, 0.2 % Casein enzymatic hydrolysate (Sigma C-0626) and 2 % Xylose)and incubated at 30°C with shaking. After 2-3 days samples of the supernatant are taken daily and analysed for PME activity.

STUDY EXPERIMENT 3

The PME expressed in *Aspergillus niger* was tested for activity by the method described earlier. The specific activity was 600 U/mg protein.

5

Characterisation of the protein by SDS-PAGE revealed a protein with MW of 36 kDa. The protein was not glycosylated as indicated by the correct MW of the mature protein. MALDI TOF MS analysis of the recombinant PME protein also showed that the enzyme was not glycosylated. From the amino acid sequence two potential N-glycosylation sites were detected.

10

The protein was N-terminal sequenced and the N-terminal sequence was: A T T Y N A V V. This result shows that both the fungal signal peptide and the signal peptide from *Erwinia* are processed correctly and the mature protein is produced without any N-terminal signal peptides.

15

The pH optimum of the *E. chrysanthemi* expressed in *A. niger* is pH 5.5 to 7. The same pH profile was also seen for the *E. chrysanthemi* PME expressed in *E. coli*.

20

The *Aspergillus* expressed *E. chrysanthemi* PME was concentrated by ultrafiltration using YM 10 membrane (Amicon) prior to enzymatic modification of pectin.

Modification of pectin with *Aspergillus* expressed PME obtainable from *Erwinia chrysanthemi*

25

Methods:

Enzymatic treatment of pectin with PME from *E. chrysanthemi*.

30

40 g GRINDSTED™ Pectin URS 1400 was dissolved in hot water under efficient stirring. 7.8 g NaCl was added and the volume adjusted to 1.33 l with water. The

pectin solution was stirred until all material had dissolved and then cooled to 37°C. pH was increased to 5.5, using 1 N NaOH and efficient stirring. 26 U of PME was added and pH and temperature was kept constant at 5.5 and 37°C by automatic dosage of 1N NaOH during about two hours, until 8 ml 1 N NaOH was consumed. pH of the solution was lowered to 3.0 by addition of 2 N HCl to stop the enzymatic reaction. The pectin solution was then heated to 70°C for 5 min to completely inactivate the enzyme. The treated pectin was precipitated with one volume isopropyl alcohol, washed with 60 vol. % isopropyl alcohol and pressed to 50% dry matter. The treated pectin was then air dried at 50°C and finally milled to a dry powder. 38.7 g enzyme treated pectin was isolated.

Results:

The pectin treated with PME from *E. chrysanthemi* which was expressed in *Aspergillus* was analysed with respect to %DE and calcium sensitivity (CS). The results showed that the enzymatic treated pectin has increased calcium sensitivity compared to the mother pectin. The enzymatic treatment results in a HE-pectin with significant higher calcium sensitivity. These are the same results which were obtained with the *E. chrysanthemi* PME expressed in *E. coli*.

	% DE	CS
GRINDSTED™ Pectin URS 1400	82.1 %	1.11
Enzymatic treated sample	75.3 %	2.01

Discussion

The bacterial PME (*Erwinia chrysanthemi*) has been isolated and characterized. URS pectin with DE 81 % has been de-esterified with this PME to modified pectins with varying DE%. The characterization of the pectin revealed that the pectin is a moderately Ca-sensitive pectin or a very Ca-sensitive pectin at a high DE%. We believe that this is

the first time that a bacterial PME has been shown to de-methylate pectin in a block-wise manner.

5 With the specific embodiment of the present invention, the modified pectin with DE of 78% has been tested in a acidified milk drink system. The results showed that the modified pectin stabilises the protein in the acidified milk drink at a concentration of 0.15% pectin. The URS pectin do only stabilise the proteins in the acidified milk drink test at a very high concentration of pectin (> 0.5).

10 Likewise, we believe that this is the first time it has been shown that a bacterial PME can de-methylate pectin in a blockwise manner and, in addition, produce a Ca-sensitive pectin and, in addition, wherein the modified pectin can stabilise acidified milk drink.

PROTOCOLS

PROTOCOL I

5

CALCIUM SENSITIVITY INDEX (CS)

Calcium sensitivity is measured as the viscosity of a pectin dissolved in a solution with 57.6 mg calcium/g pectin divided by the viscosity of exactly the same amount of pectin in solution, but without added calcium. A calcium insensitive pectin has a CS value of 1.

10

4.2 g pectin sample is dissolved in 550 ml hot water with efficient stirring. The solution is cooled to about 20°C and the pH adjusted to 1.5 with 1N HCl. The pectin solution is adjusted to 700 ml with water and stirred. 145 g of this solution is measured individually into 4 viscosity glasses. 10 ml water is added to two of the glasses (double determinations) and 10 ml of a 250 mM CaCl₂ solution is added to the other two glasses under stirring.

15

50 ml of an acetate buffer (0.5 M, pH about 4.6) is added to all four viscosity glasses under efficient magnetic stirring, thereby bringing the pH of the pectin solution up over pH 4.0. The magnets are removed and the glasses left overnight at 20°C. The viscosities are measured the next day with a Brookfield viscometer. The calcium sensitivity index is calculated as follows:

20

$$\text{CS} = \frac{\text{Viscosity of a solution with 57.6 mg Ca}^{2+} / \text{g pectin}}{\text{Viscosity of a solution with 0.0 mg Ca}^{2+} / \text{g pectin}}$$

25

PROTOCOL II**DEGREE OF ESTERIFICATION (%DE)**

- 5 To 50 ml of a 60 % isopropanol and a 5 % HCl solution is added 2.5 g pectin sample and stirred for 10 min. The pectin solution is filtered through a glass filter and washed with 15 ml 60 % isopropanol/5 % HCl solution 6 times followed by further washes with 60% isopropanol until the filtrate is free of chlorides. The filtrate is dried overnight at 80°C.
- 10 20.0 ml 0.5 N NaOH and 20.0 ml 0.5 N HCl is combined in a conical flask and 2 drops of phenolphthalein is added. This is titrated with 0.1 N NaOH until a permanent colour change is obtained. The 0.5 N HCl should be slightly stronger than the 0.5N NaOH. The added volume of 0.1 N NaOH is noted as V_0 .
- 15 0.5 g of the dried pectin sample (the filtrate) is measured into a conical flask and the sample is moistened with 96% ethanol. 100 ml of recently boiled and cooled distilled water is added and the resulting solution stirred until the pectin is completely dissolved. Then 5 drops of phenolphthalein are added and the solution titrated with 0.1 N NaOH (until a change in colour and pH is 8.5). The amount of 0.1 N NaOH used here is noted as V_1 .
- 20 20.0 ml of 0.5 N NaOH is added and the flask shaken vigously, and then allowed to stand for 15 min. 20.0 ml of 0.5 N HCl is added and the flask is shaken until the pink colour disappears. 3 drops of phenolphthalein are then added and then the resultant solution is titrated with 0.1 N NaOH. The volume 0.1 N NaOH used is noted as V_2 .
- 25 The degree of esterification (% DE: % of total carboxy groups) is calculated as follows:

$$\% \text{ DE} = \frac{V_2 - V_0}{V_1 + (V_2 - V_0)}$$

PROTOCOL III

DRINK TEST

1. Introduction

5

The following describes a protocol that only uses about 1.7 g pectin to as little as possible. The methods used to evaluate the performance of the system are viscometry, centrifugal sedimentation, and particle size determination.

2. Materials and methods

2.1 Materials

15

Skim milk powder with approx. 36% protein was obtained from Mejeriernes Fælles Indkøb (Kolding, Denmark). Pectins for testing were obtained by treatment of a pectin with a modified PME according to the present invention. These pectins may have different properties such as degree of esterification and molecular weight, depending on the type of modified PME used.

2.2 Preparation of milk drink

20

The milk drinks were made by mixing an acidified milk solution and a pectin solution, followed by further processing.

25

A milk solution was made by dissolving 17% (w/w) skimmilk powder in distilled water at 68°C and stirring for 30 min. The milk solution was then acidified to pH 4.1 at 30°C by addition of 3% (w/w) glucono-d-lactone (GDL).

30

The pectin solution was made up in several steps. First pectin was dry mixed with dextrose at a 3:2 weight ratio, and then a 1.11% (w/w) solution of this mixture in distilled water was made. The last step in the preparation of the pectin solution was to add sucrose to an end concentration of 17.8% (w/w).

Milk drinks were then prepared by mixing 1 part of milk solution with 1.13 parts (w/w) of pectin solution, followed by heat treatment (see section 3.2) and homogenisation at 20-22 MPa and 20°C using a Mini Jet Homogeniser (Burgaud et. al., 1990). By following this procedure, the final concentration of pectin in the milk drink was 0.3% (w/w). All samples were produced in duplicate, stored at 5°C and tested for viscosity, particle size and sedimentation the following day.

2.3 Viscosity measurement

The viscosity was measured using a Bohlin VOR Rheometer system (Bohlin Instruments, Metric Group Ltd., Gloucestershire, Great Britain). Thermostatisation was achieved by a Bohlin lower-plate temperature control unit. The viscosity was measured at a shear rate of 91.9 s^{-1} . The measuring temperature was 20°C, and the samples were held at 20°C for approximately 1 hour before measurement. The measuring system used was C 14 (a coaxial cylindrical system). The torque element used was 0.25 g cm. Integration time was 5 s, measurement interval was 30 s, and no autozero was used. Instrumental control and primary data processing were done on a PC with the Bohlin Rheometer Software version 4.05.

2.4 Particle size measurement

The particle mean diameter, $D[4.3]$, was measured with a Malvern Mastersizer Micro Plus (Malvern Instruments Limited, Worcestershire, UK). Instrumental settings were: presentation code: 5NBD, and Analysis Model: polydisperse. Instrumental control and primary data processing were done on a PC with Mastersizer Microplus for Windows, version 2.15.

Ultrafiltration permeate obtained from a batch of acidified milk drink made with pectin no. 4 was used for dilution. Ultrafiltration was done using a DDS UF Lab 20-0.36 module fitted with GR61PP membranes, having a molecular weight cut-off of 20.000 Da.

2.5 Sedimentation

Sedimentation measurements were performed by centrifugation of the samples using an IEC Centra-8R Centrifuge (International Equipment, Needham Hts, MA, USA). 2.5 g acidified milk drink was centrifuged for 25 min at 20°C and 2400 g. The supernatant was removed, the tubes were left up side down for 15 min, and the weight of the sediment was determined and expressed as a percentage (of the amount of milk drink used). Duplicate measurements were made of each sample.

3. Results and discussion

3.1 Size of test system

This new system is small compared to the previous test systems but it still maintains the same properties as the existing test system based on 550 g acidified milk drink. The easiest way to make a model system for testing pectins in acidified milk drinks would be to simply mix stirred acidified milk drink with a pectin solution, and make the measurements on this mixture. This also has the advantage that it can be done virtually at any scale. However, Glahn and Rolin showed that a homogenisation reduces the amount of pectin needed for stabilisation and that both homogenisation and heat treatment have very considerable effects on stability. Since both homogenisation and heat treatment were included in the existing system at 550 g scale, as they are in industrial processes, both treatments also needed to be present in the small scale system.

In industry both upstream (before heating) and downstream (after heating) homogenisation is used. In this model system we chose to put the homogenisation in after heat treatment because this gives a more homogeneous sample, and thereby makes it easier to obtain reproducible measurements of e.g. viscosity.

To achieve a reproducible homogenisation with the Mini Jet Homogeniser, and to compensate for various losses during sample transfer, it was desirable to operate with 40 ml of sample at the homogenisation stage. Since only 8-9 ml was needed for the tests

(2.5 ml for viscometry, 5 ml for sedimentation, and 0.5-1 ml for particle size determination), the step that required the largest amount of sample was the homogenisation, and the result was therefore that the existing test system was scaled down from 550 g to 40 g milk drink.

5

3.2 Heat treatment

To make the scaled down system mimic the existing test system as closely as possible it was desirable to make modifications to the heat treatment step. With the existing 550 g system heating took place in a 600 ml Blue-cap bottle for 30 min in a 75°C water bath, with stirring every 5 minutes.

10

With the new 40 g system the heat treatment was done in a 50 ml plastic centrifuge tube placed inside a 600 ml Blue-cap bottle filled with water. Here 75°C in the water bath gave too strong a heating, probably because the thermal conductivity of water is larger than that of coagulated milk. Different temperatures between 70 and 75°C were therefore tested, and it was found that 72°C for 30 minutes, without stirring, gave a good approximation to the temperature profile in the large system.

15

3.3 Testing of small scale system

If a milk drink stabilised with a pectin treated with a modified PME according to the present invention showed little sedimentation and small particles, then that indicates a good pectin to use and moreover is indicative that the modified PME according to the present invention is suitable for such a use.

20

4. Conclusion

25

A system for testing the stabilising power of pectins in acidified milk drinks has successfully been scaled down from 550 g to 40 g milk drink, meaning that the required amount of pectin is reduced from ca. 1.7 g to ca. 0.15 g. This is small enough to allow screening of experimental pectin samples treated with modified pectins according to the present invention. A high correlation between results obtained for particle size, viscosity

30

and sedimentation between the two methods has been demonstrated. The scaled down method is relatively simple, although it still contains both heating and homogenisation, which is considered important for industrial relevance.

PROTOCOL IVPME ACTIVITY

5 PME catalyses the cleavage of methylester groups from pectin. During the purification steps PME can be detected by a fast method using methyl red indicator test. Due to cleavage of methyl groups from galacturonic acid residues in the pectin chain, carboxyl groups are formed and the pH will then drop in the assay. The pH indicator - methyl red - changes colour at pH drop from yellow (pH 6.2) to pink (pH 4.2). Typically, the assay
10 will contain 1 ml 0.5 % GrindstedTM Pectin 1450 (DE 70%) (supplied by Danisco Ingredients, Danisco A/S) solubilized in 0.15 M NaCl pH 7 and 25 µl sample. The samples which then show positive methyl red test after 10 min incubation at 30°C are then further measured by the titration method (Versteeg et al (1978) Lebensmittel.-Wiss. u. Technol., 11: 267-274).

15

With the titration method the assay will typically contain 10 ml 0.5 % lime pectin (GrindstedTM Pectin 1450 - supplied by Danisco Ingredients, Danisco A/S) solubilized in 0.15 M NaCl pH 6.8 and 10 - 100 µl sample. Titration is performed with 0.02 M NaOH and the reaction is measured at room temperature. An automatic titrator can be used
20 (Versteeg et al. (1978) Lebensmittel.-Wiss. u. Technol., 11: 267-274).

For convenience, we now present a Table indicating the codes used for the amino acids.

AMINO ACID	THREE LETTER ABBREVIATION	ONE LETTER SYMBOL
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V
Any residue	Xaa	X

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection
5 with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

REFERENCES

- 5 Glahn, P.E., Rolin, C.: Food Ingredients Europe, Conf . Proc. 252-256 (1994)
- Burgaud, I., Dickinson, E., Nelson, E.: International Journal of Food Science and
Technology 25, 39-46 (1990)
- 10 Finer JJ, Vain P, Jones MW & McMullen MD (1992)
 Development of the particle inflow gun for DNA delivery to plant cells
 Plant cell Reports 11: 323-328
- 15 Klein TM, Wolf ED, Wu R & Sanford JC (1987)
 High-velocity microprojectiles for delivery nucleic acids into living cells
 Nature 327: 70-73
- 20 Sanford JC, Klein TM, Wolf ED & Allen N (1987)
 Delivery of substances into cells and tissues using a particle bombardment process
 Particulate Science and Technology 5: 27-37
- Vain P, Keen N, Murillo J, Rathus C, Nemes C & Finer JJ (1993)
 Development of the Particle Inflow Gun
 Plant cell, Tissue and Organ Culture 33: 237-246
- 25 Penninga D, van der Veen BA, Knegtel RMA, van Hijum SAFT, Rozeboom HJ, Kalk
 KH, Dijkstra BW, Dijkhuizen L. (1996) The raw starch binding domain of cyclodextrin
 glycosyltransferase from *Bacillus circulans* strain 251. J. Biol. Chem. 271: 2777-32784.

EDITORIAL NOTE 56441/99

SEQUENCE LISTING PAGE 1 IS PART OF THE DESCRIPTION AND
IS FOLLOWED BY CLAIM PAGES 83 TO 86.

SEQUENCES

SEQ.I.D. NO. 1

FPECTINESTERASE cDNA FROM
ERWINIA CHRYSANTEMII

5
10
15
20
25
ATGTTAAAAA CGATCTCTGG AACCCCTCGCG CTGTCGCTGA TTATCGCTGC CAGCGTACAT
CAGGCACAGG CAGCGACCAC CTACAACGCT GTGGTATCAA AATCCTCCAG CGACGGCAAA
ACAATCAAAA CTATTGCCGA CGCAATTGCC AGCGCCCCAG CAGGCAGCAC GCCGTTCGTC
ATTTTGATCA AGAACGGCGT CTATAATGAA CGCCTGACGA TTACCCGCAA TAACCTGCAT
CTGAAAGGCG AAAGTCGTAA CGGTGCGGTC ATTGCGGCTG CCACGGCGGC GGGCACCCCTG
AAATCGGACG GCAGCAAGTG GGGAACGGCA GGCAGCAGCA CCATCACCAT CAGCGCCAAG
GATTTTCAGCG CCCAGTCGCT GACCATTTCGC AACGACTTTG ATTTCCCGGC CAATCAGGCC
AAAAGCGACA GCGACAGCAG TAAAATCAAG GACACGCAGG CAGTTGCGCT CTATGTCACC
AAAAGCGGCG ACCGCGCCTA CTTCAAAGAC GTCAGTCTGG TCGGCTATCA GGACACGCTG
TATGTTTCCG GCGGCCGCAG TTTCTTCTCC GACTGCCGTA TCAGCGGCAC GGTGACTTT
ATCTTTGGCG ACGGCACCGC GCTGTTCAAC AACTGCGATC TGGTTTCCCG CTATCGCGCT
GATGTGAAAA GCGGCAATGT TTCCGGCTAC CTGACCGCGC CCAGCACCAA CATCAATCAG
AAGTATGGCC TGGTGATCAC CAACAGTCGC GTGATACGGG AAAGTGACTC TGTACCGGCG
AAAAGCTACG GGCTGGGTCG CCCCTGGCAT CCAACAACAA CCTTCTCTGA TGGCCGTTAC
GCGAATCCGA ACGCTATTGG TCAGACCGTT TTCCTGAACA CCAGCATGGA TAATCATATT
TATGGTTGGG ACAAGATGTC CGGCAAGGAC AAAACGGCA ACACCATCTG GTTCAACCCG
GAAGATTCCC GTTTCTTCGA GTACAAATCC TATGGCGCGG GAGCGGCGGT GAGCAAAGAC
CGCCGACAGT TGA CTGACGC ACAGGCGGCA GAGTACACGC AGAGCAAAGT CCTGGGCGAC
TGGACGCCGA CATTACCCTG A

SEQ.I.D. NO. 2

30
FPECTINESTERASE FROM
ERWINIA CHRYSANTEMII

35
40
MLKTISGTLA LSLIIAASVH QAQAATTYNA VVSKSSSDGK TIKTIADAIA SAPAGSTPFV
ILIKNGVYNE RLITRNNLH LKGESRNGAV IAAATAAGTL KSDGSKWGTA GSSTITISAK
DFSAQSLTIR NDFDFPANQA KSDSDSSKIK DTQAVLYVT KSGDRAYFKD VSLVGYQDTL
YVSGGRSFFS DCRISGTVDF IFGDGTALFN NCDLVSRYRA DVKSGNVSGY LTAPSTNINQ
KYGLVITNSR VIRESDSVPK KSYGLGRPWH PTTTFSDGRY ANPNAIGQTV FLNTSMDNHI
YGWDKMSGKD KNGNTIWFNP EDSRFFEYKS YGAGAAVSKD RRQLTDAQAA EYTQSKVLGD
WTPTLP

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A process for treating a pectin with a pectin methyl esterase (PME) to produce a PME-treated high ester pectin comprising the step of contacting a pectin with an
5 *Erwinia* PME wherein the PME results in block-wise de-esterification of the pectin.
2. A process according to claim 1 wherein the PME has a molecular weight of about 36,000 D and/or a pI of about >9 and/or a pH optimum with lime pectin (as determined by the aforementioned method) of about pH 7 and/or a temperature
10 optimum with lime pectin (as determined by the aforementioned method) of about 48°C.
3. A process according to claim 1 or claim 2 wherein the PME comprises the amino acid sequence shown as SEQ ID NO: 2, or a variant, derivative or homologue
15 thereof, including combinations thereof.
4. A process according to any one of the preceding claims wherein the PME has the amino acid sequence shown as SEQ ID NO: 2, or a variant, derivative or homologue thereof.
20
5. A process according to any one of the preceding claims wherein the PME has the amino acid sequence shown as SEQ ID NO: 2.
6. A process according to any one of the preceding claims wherein the PME has
25 been expressed by a nucleotide sequence comprising the nucleotide sequence shown as SEQ ID NO: 1, or a variant, derivative or homologue thereof, or combinations thereof.
7. A process according to any one of the preceding claims wherein the PME has been expressed by a nucleotide sequence having the nucleotide sequence shown as
30 SEQ ID NO: 1, or a variant, derivative or homologue thereof.
8. A process according to any one of the preceding claims wherein the PME has been expressed by a nucleotide sequence having the nucleotide sequence shown as SEQ ID NO: 1.



9. A process according to any one of the preceding claims wherein the PME has been prepared by use of DNA techniques.

10. A process according to any one of the preceding claims wherein the pectin is
5 treated by the PME in the presence of sodium ions.

11. A process according to claim 10 wherein the sodium ions are derived from NaCl, NaNO₃ or Na₂SO₄ or combinations thereof.

10 12. A process according to any one of the preceding claims wherein the process includes the further step of isolating the PME treated pectin from the active PME.

13. A process according to claim 12 wherein the PME treated pectin contains from about 70% to about 80% ester groups.

15

14. A process according to claim 12 or claim 13 wherein the PME treated pectin contains from about 72% to about 80% ester groups.

15. A process according to any one of claims 12 to 14 wherein the PME treated
20 pectin contains from about 74% to about 80% ester groups.

16. A process according to any one of claims 12 to 15 wherein the PME treated pectin contains from about 76% to about 80% ester groups.

25 17. A process according to any one of claims 12 to 16 wherein the PME treated pectin contains about 77% to about 80% ester groups.

18. A process according to any one of the preceding claims wherein the process includes the further step of adding the PME treated pectin to a medium that is suitable
30 for consumption.

19. A process according to claim 18 wherein the medium is an aqueous solution.

20. A process according to claim 18 or claim 19 wherein the aqueous solution is a
35 beverage.



21. A process according to any one of claims 18 to 20 wherein the medium is an acidic environment.

22. A process according to claim 21 wherein the acidic environment has a pH of
5 from about 3.5 to about 5.5, preferably wherein the acidic environment has a pH of from 4 to about 5.5.

23. A process according to claim 22, wherein the acidic environment has a pH of about 4.

10

24. A process according to any one of claims 18 to 23 wherein the beverage is an acidified milk drink.

25. A process according to any one of claims 18 to 24 wherein the medium
15 comprises and/or is enriched with a protein.

26. A process according to claim 25 wherein the protein is derived from or is derivable from or is in a dairy product.

20 27. A process according to claim 25 wherein the protein is derived from or is derivable from or is in a plant product.

28. A PME treated pectin prepared by the process according to any one of the preceding claims.
25

29. A foodstuff comprising a PME treated pectin prepared by the process according to any one of the preceding claims

30. Use of a PME as defined in any one of claims 3 to 9 to reduce the number of
30 ester groups in a pectin and in a block-wise manner.

31. Use of a PME as defined in any one of claims 3 to 9 to de-esterify two or more adjacent galacturonic acid residues of a pectin on at least substantially all of the pectin chains.

35



32. A process according to any one of claims 1 to 27 substantially as hereinbefore described with particular reference to the examples.

33. A PME treated pectin according to claim 28 substantially as hereinbefore
5 described with particular reference to the examples.

34. A foodstuff according to claim 29 substantially as hereinbefore described with particular reference to the examples.

10 35. Use according to claims 30 or 31 substantially as hereinbefore described with particular reference to the examples.

Dated this twenty-fourth day of January 2003

DANISCO A/S

Patent Attorneys for the Applicant:

F B RICE & CO



Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

